US5800815A
(en)
*
|
1903-05-05 |
1998-09-01 |
Cytel Corporation |
Antibodies to P-selectin and their uses
|
US5851526A
(en)
*
|
1985-04-19 |
1998-12-22 |
Ludwig Institute For Cancer Research |
Methods of treating colon cancer utilizing tumor-specific antibodies
|
US5449760A
(en)
*
|
1987-12-31 |
1995-09-12 |
Tanox Biosystems, Inc. |
Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
|
US5530101A
(en)
*
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
US7247453B1
(en)
*
|
1988-12-30 |
2007-07-24 |
Oklahoma Medical Research Foundation |
Calcium binding recombinant antibody against protein C
|
DE3900534A1
(de)
*
|
1989-01-10 |
1990-07-12 |
Boehringer Mannheim Gmbh |
Diagnostischer nachweis unter verwendung von chimaeren antikoerpern
|
GB8928874D0
(en)
|
1989-12-21 |
1990-02-28 |
Celltech Ltd |
Humanised antibodies
|
US6750325B1
(en)
|
1989-12-21 |
2004-06-15 |
Celltech R&D Limited |
CD3 specific recombinant antibody
|
US5859205A
(en)
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
GR1001050B
(el)
*
|
1990-01-09 |
1993-04-28 |
Protein Design Labs Inc |
Νεος il-2 υποδοχευς ιδιαζοντων ανθρωπινων ανοσοσφαιρινων.
|
HUT60768A
(en)
|
1990-03-16 |
1992-10-28 |
Sandoz Ag |
Process for producing cd25 fixing molecules
|
GB9020282D0
(en)
|
1990-09-17 |
1990-10-31 |
Gorman Scott D |
Altered antibodies and their preparation
|
US5858725A
(en)
*
|
1990-10-10 |
1999-01-12 |
Glaxo Wellcome Inc. |
Preparation of chimaeric antibodies using the recombinant PCR strategy
|
US5994510A
(en)
*
|
1990-12-21 |
1999-11-30 |
Celltech Therapeutics Limited |
Recombinant antibodies specific for TNFα
|
CA2082160C
(en)
*
|
1991-03-06 |
2003-05-06 |
Mary M. Bendig |
Humanised and chimeric monoclonal antibodies
|
IL101147A
(en)
*
|
1991-03-07 |
2004-06-20 |
Gen Hospital Corp |
Change of direction of cellular immunity by chimera receptors
|
ATE169031T1
(de)
*
|
1991-04-05 |
1998-08-15 |
Univ Washington |
Zellrezeptor spezifische monoklonale antikörper gegen stammzell-faktor-rezeptor
|
US5795965A
(en)
*
|
1991-04-25 |
1998-08-18 |
Chugai Seiyaku Kabushiki Kaisha |
Reshaped human to human interleukin-6 receptor
|
DE69233482T2
(de)
*
|
1991-05-17 |
2006-01-12 |
Merck & Co., Inc. |
Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
|
US6407213B1
(en)
|
1991-06-14 |
2002-06-18 |
Genentech, Inc. |
Method for making humanized antibodies
|
US6800738B1
(en)
|
1991-06-14 |
2004-10-05 |
Genentech, Inc. |
Method for making humanized antibodies
|
WO1994004679A1
(en)
*
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
GB9115010D0
(en)
*
|
1991-07-11 |
1991-08-28 |
Wellcome Found |
Antibody
|
GB9115364D0
(en)
|
1991-07-16 |
1991-08-28 |
Wellcome Found |
Antibody
|
US5709860A
(en)
*
|
1991-07-25 |
1998-01-20 |
Idec Pharmaceuticals Corporation |
Induction of cytotoxic T-lymphocyte responses
|
IE922437A1
(en)
*
|
1991-07-25 |
1993-01-27 |
Idec Pharma Corp |
Recombinant antibodies for human therapy
|
US6136310A
(en)
|
1991-07-25 |
2000-10-24 |
Idec Pharmaceuticals Corporation |
Recombinant anti-CD4 antibodies for human therapy
|
CZ288048B6
(cs)
*
|
1991-07-25 |
2001-04-11 |
Idec Pharmaceuticals Corporation |
Farmaceutická kompozice k indukci cytotoxické odpovědi T-lymfocytů
|
US5756096A
(en)
*
|
1991-07-25 |
1998-05-26 |
Idec Pharmaceuticals Corporation |
Recombinant antibodies for human therapy
|
US6329509B1
(en)
*
|
1991-08-14 |
2001-12-11 |
Genentech, Inc. |
Anti-IgE antibodies
|
US6685939B2
(en)
|
1991-08-14 |
2004-02-03 |
Genentech, Inc. |
Method of preventing the onset of allergic disorders
|
ES2145004T3
(es)
*
|
1991-08-21 |
2000-07-01 |
Novartis Ag |
Derivados de anticuerpos.
|
GB9120467D0
(en)
*
|
1991-09-26 |
1991-11-06 |
Celltech Ltd |
Anti-hmfg antibodies and process for their production
|
JP3024311B2
(ja)
*
|
1991-10-03 |
2000-03-21 |
味の素株式会社 |
Il−2受容体重鎖に結合するポリペプチド
|
US5474771A
(en)
*
|
1991-11-15 |
1995-12-12 |
The Trustees Of Columbia University In The City Of New York |
Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
|
US7070777B1
(en)
|
1991-11-15 |
2006-07-04 |
The Trustees Of Columbia University In The City Of New York |
Method for inhibiting inflammation with an antibody that binds the 5C8 protein
|
US5817310A
(en)
*
|
1991-12-02 |
1998-10-06 |
Cor Therapeutics, Inc. |
Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
|
JPH05244982A
(ja)
*
|
1991-12-06 |
1993-09-24 |
Sumitomo Chem Co Ltd |
擬人化b−b10
|
US5869619A
(en)
*
|
1991-12-13 |
1999-02-09 |
Xoma Corporation |
Modified antibody variable domains
|
CA2507749C
(en)
*
|
1991-12-13 |
2010-08-24 |
Xoma Corporation |
Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
|
US5777085A
(en)
*
|
1991-12-20 |
1998-07-07 |
Protein Design Labs, Inc. |
Humanized antibodies reactive with GPIIB/IIIA
|
US5824307A
(en)
|
1991-12-23 |
1998-10-20 |
Medimmune, Inc. |
Human-murine chimeric antibodies against respiratory syncytial virus
|
DE69333807T2
(de)
*
|
1992-02-06 |
2006-02-02 |
Chiron Corp., Emeryville |
Marker für krebs und biosynthetisches bindeprotein dafür
|
GB9203459D0
(en)
*
|
1992-02-19 |
1992-04-08 |
Scotgen Ltd |
Antibodies with germ-line variable regions
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
US5387676A
(en)
*
|
1992-03-11 |
1995-02-07 |
Ciba Corning Diagnostics Corp. |
MN gene and protein
|
US6129914A
(en)
*
|
1992-03-27 |
2000-10-10 |
Protein Design Labs, Inc. |
Bispecific antibody effective to treat B-cell lymphoma and cell line
|
US7381803B1
(en)
|
1992-03-27 |
2008-06-03 |
Pdl Biopharma, Inc. |
Humanized antibodies against CD3
|
US6033667A
(en)
*
|
1992-05-05 |
2000-03-07 |
Cytel Corporation |
Method for detecting the presence of P-selectin
|
US5874082A
(en)
*
|
1992-07-09 |
1999-02-23 |
Chiron Corporation |
Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
|
US5397703A
(en)
*
|
1992-07-09 |
1995-03-14 |
Cetus Oncology Corporation |
Method for generation of antibodies to cell surface molecules
|
US5639641A
(en)
*
|
1992-09-09 |
1997-06-17 |
Immunogen Inc. |
Resurfacing of rodent antibodies
|
US5958708A
(en)
*
|
1992-09-25 |
1999-09-28 |
Novartis Corporation |
Reshaped monoclonal antibodies against an immunoglobulin isotype
|
US6066718A
(en)
*
|
1992-09-25 |
2000-05-23 |
Novartis Corporation |
Reshaped monoclonal antibodies against an immunoglobulin isotype
|
GB9223377D0
(en)
*
|
1992-11-04 |
1992-12-23 |
Medarex Inc |
Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
|
DK0669836T3
(da)
|
1992-11-13 |
1996-10-14 |
Idec Pharma Corp |
Terapeutisk anvendelse af kimære og radioaktivt mærkede antistoffer og humant B-lymfocytbegrænset differentieringsantigen til behandling af B-cellelymfom
|
US5736137A
(en)
*
|
1992-11-13 |
1998-04-07 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
US7744877B2
(en)
|
1992-11-13 |
2010-06-29 |
Biogen Idec Inc. |
Expression and use of anti-CD20 Antibodies
|
US5648267A
(en)
*
|
1992-11-13 |
1997-07-15 |
Idec Pharmaceuticals Corporation |
Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
|
ATE236987T1
(de)
*
|
1992-11-13 |
2003-04-15 |
Idec Pharma Corp |
Konsensus-kozak-sequenzen zur säugetier- exprimierung
|
US5804187A
(en)
*
|
1992-11-16 |
1998-09-08 |
Cancer Research Fund Of Contra Costa |
Modified antibodies with human milk fat globule specificity
|
EP0678122B1
(de)
*
|
1993-01-12 |
1999-07-28 |
Biogen, Inc. |
Rekombinante anti-vla4 antikörpermoleküle
|
US5817311A
(en)
*
|
1993-03-05 |
1998-10-06 |
Universite Catholique De Louvain |
Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies
|
US5730979A
(en)
*
|
1993-03-05 |
1998-03-24 |
Universite Catholique Delouvain |
LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation
|
US5951983A
(en)
*
|
1993-03-05 |
1999-09-14 |
Universite Catholique De Louvain |
Methods of inhibiting T cell mediated immune responses with humanized LO-CD2A-specific antibodies
|
WO1994025067A1
(en)
*
|
1993-05-04 |
1994-11-10 |
Cytel Corporation |
Antibodies to p-selectin and their uses
|
JPH08510909A
(ja)
*
|
1993-05-28 |
1996-11-19 |
ザ スクリップス リサーチ インスティチュート |
Cd14媒介細胞活性化を抑制するための方法および組成物
|
WO1994028159A1
(fr)
*
|
1993-05-31 |
1994-12-08 |
Chugai Seiyaku Kabushiki Kaisha |
Anticorps humain reconstruit contre l'interleukine-6 humaine
|
US6180377B1
(en)
*
|
1993-06-16 |
2001-01-30 |
Celltech Therapeutics Limited |
Humanized antibodies
|
US20020193575A1
(en)
|
1993-09-07 |
2002-12-19 |
Smithkline Beecham P.L.C. |
Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
|
US5914110A
(en)
*
|
1993-09-07 |
1999-06-22 |
Smithkline Beecham Corporation |
Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
|
HU222041B1
(hu)
*
|
1993-09-07 |
2003-04-28 |
Smithkline Beecham Corporation |
Az IL4 által kőzvetített rendellenességek kezelésére használható rekombináns 1L4 antitestek, eljárás ezek előállítására, alkalmazására és az őket tartalmazó gyógyszerkészítmények
|
US5928904A
(en)
*
|
1993-09-07 |
1999-07-27 |
Smithkline Beecham Corporation |
DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
|
US6214973B1
(en)
|
1993-11-19 |
2001-04-10 |
Chugai Seiyaku Kabushiki Kaisha |
Reshaped human antibody to human medulloblastoma cells
|
AU2185195A
(en)
*
|
1993-11-30 |
1995-06-19 |
Protein Design Labs, Inc. |
Reperfusion therapy using antibodies to L-selectin
|
GB9325182D0
(en)
*
|
1993-12-08 |
1994-02-09 |
T Cell Sciences Inc |
Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions
|
US7435802B2
(en)
|
1994-01-25 |
2008-10-14 |
Elan Pharaceuticals, Inc. |
Humanized anti-VLA4 immunoglobulins
|
CA2182013C
(en)
*
|
1994-01-25 |
2007-07-17 |
Mary M. Bendig |
Humanized antibodies against leukocyte adhesion molecule vla-4
|
US5840299A
(en)
*
|
1994-01-25 |
1998-11-24 |
Athena Neurosciences, Inc. |
Humanized antibodies against leukocyte adhesion molecule VLA-4
|
GB2301366B
(en)
|
1994-03-29 |
1998-07-29 |
Celltech Therapeutics Ltd |
Antibodies against E-selectin
|
US5635597A
(en)
*
|
1994-05-27 |
1997-06-03 |
Affymax Technologies, N.V. |
Peptides that bind IL-2 receptors
|
US5622701A
(en)
|
1994-06-14 |
1997-04-22 |
Protein Design Labs, Inc. |
Cross-reacting monoclonal antibodies specific for E- and P-selectin
|
USRE39548E1
(en)
*
|
1994-06-17 |
2007-04-03 |
Celltech R&D Limited |
Interleukin-5 specific recombinant antibodies
|
GB9412230D0
(en)
|
1994-06-17 |
1994-08-10 |
Celltech Ltd |
Interleukin-5 specific recombiant antibodies
|
US6048972A
(en)
*
|
1994-07-13 |
2000-04-11 |
Chugai Pharmaceutical Co., Ltd. |
Recombinant materials for producing humanized anti-IL-8 antibodies
|
DE4425115A1
(de)
*
|
1994-07-15 |
1996-01-18 |
Boehringer Mannheim Gmbh |
Verfahren zur Modifizierung der Stabilität von Antikörpern
|
EP0696455A1
(de)
*
|
1994-08-11 |
1996-02-14 |
Cellena (Cell Engineering) A.G. |
Transferrin Zusammensetzungen zur Erleichterung der Nebenwirkungen der cytotoxischen Medikamente
|
US8771694B2
(en)
*
|
1994-08-12 |
2014-07-08 |
Immunomedics, Inc. |
Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells
|
US5707621A
(en)
*
|
1994-08-31 |
1998-01-13 |
Chugai Pharmaceutical Co., Ltd. |
Supression of nephritis-induced protein excretion by anti-IL-8
|
US6309636B1
(en)
*
|
1995-09-14 |
2001-10-30 |
Cancer Research Institute Of Contra Costa |
Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
|
US5683892A
(en)
*
|
1994-12-23 |
1997-11-04 |
Smithkline Beecham Corporation |
DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
|
WO1996040249A1
(en)
*
|
1995-06-07 |
1996-12-19 |
Sloan-Kettering Institute For Cancer Research |
Therapeutic uses of ta99
|
US6113898A
(en)
|
1995-06-07 |
2000-09-05 |
Idec Pharmaceuticals Corporation |
Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
|
US7153508B2
(en)
|
1995-06-07 |
2006-12-26 |
Biogen Idec Inc. |
Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
|
US5811524A
(en)
*
|
1995-06-07 |
1998-09-22 |
Idec Pharmaceuticals Corporation |
Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
|
US7175847B1
(en)
|
1995-06-07 |
2007-02-13 |
Biogen Idec Inc. |
Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
|
US6440418B1
(en)
|
1995-11-07 |
2002-08-27 |
Idec Pharmaceuticals Corporation |
Methods of treating autoimmune diseases with gp39-specific antibodies
|
US6001358A
(en)
|
1995-11-07 |
1999-12-14 |
Idec Pharmaceuticals Corporation |
Humanized antibodies to human gp39, compositions containing thereof
|
GB9600660D0
(en)
|
1996-01-12 |
1996-03-13 |
Ciba Geigy Ag |
Protein
|
AU2527397A
(en)
*
|
1996-03-13 |
1997-10-01 |
Protein Design Labs, Inc. |
Fas ligand fusion proteins and their uses
|
US5882644A
(en)
*
|
1996-03-22 |
1999-03-16 |
Protein Design Labs, Inc. |
Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
|
US6713305B1
(en)
|
1996-04-29 |
2004-03-30 |
Novartis Ag |
Metastasis-associated antigen and antibodies thereto
|
JP4503706B2
(ja)
|
1996-06-07 |
2010-07-14 |
ポニアード ファーマシューティカルズ,インコーポレイティド |
グリコシル化が改質されたヒト化抗体
|
US6534311B2
(en)
|
1996-07-24 |
2003-03-18 |
Novartis Ag |
Drosophila melanogaster p70S6 kinase
|
US6833255B1
(en)
|
1996-07-24 |
2004-12-21 |
Novartis, Ag |
Drosophila melanogaster p70 S6 kinase
|
US7147851B1
(en)
*
|
1996-08-15 |
2006-12-12 |
Millennium Pharmaceuticals, Inc. |
Humanized immunoglobulin reactive with α4β7 integrin
|
CA2264968A1
(en)
*
|
1996-09-02 |
1998-03-12 |
Sumitomo Electric Industries, Ltd. |
Humanized immunoglobulin reacting specifically with fas ligand or active fragments thereof and region inducing apoptosis originating in fas ligand
|
US6013256A
(en)
*
|
1996-09-24 |
2000-01-11 |
Protein Design Labs, Inc. |
Method of preventing acute rejection following solid organ transplantation
|
RU2198220C2
(ru)
|
1996-09-26 |
2003-02-10 |
Чугаи Сейяку Кабусики Кайся |
Антитело против белка, родственного паращитовидному гормону человека, днк, вектор, способ получения и использование антитела
|
UA76934C2
(en)
|
1996-10-04 |
2006-10-16 |
Chugai Pharmaceutical Co Ltd |
Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
|
US7883872B2
(en)
|
1996-10-10 |
2011-02-08 |
Dyadic International (Usa), Inc. |
Construction of highly efficient cellulase compositions for enzymatic hydrolysis of cellulose
|
US20020160005A1
(en)
|
1996-11-15 |
2002-10-31 |
Trustees Of Tufts College |
Human neutralizing antibodies against hemolytic urmec syndrome
|
US7910096B2
(en)
|
1996-11-15 |
2011-03-22 |
Trustees Of Tufts College |
Human neutralizing antibodies against hemolytic uremic syndrome
|
EP0951551B9
(de)
|
1996-12-23 |
2012-12-26 |
Immunex Corporation |
Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie
|
US6262238B1
(en)
*
|
1997-01-14 |
2001-07-17 |
Roche Diagnostic, Gmbh |
Process for modifying the stability of antibodies
|
US6596850B1
(en)
|
1998-01-30 |
2003-07-22 |
Ixsys, Incorporated |
Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same
|
US6590079B2
(en)
|
1997-01-30 |
2003-07-08 |
Ixsys, Incorporated |
Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
|
US20030109680A1
(en)
|
2001-11-21 |
2003-06-12 |
Sunol Molecular Corporation |
Antibodies for inhibiting blood coagulation and methods of use thereof
|
US20060235209A9
(en)
|
1997-03-10 |
2006-10-19 |
Jin-An Jiao |
Use of anti-tissue factor antibodies for treating thromboses
|
US5986065A
(en)
|
1997-03-10 |
1999-11-16 |
Sunol Molecular Corporation |
Antibodies for inhibiting blood coagulation and methods of use thereof
|
US7749498B2
(en)
|
1997-03-10 |
2010-07-06 |
Genentech, Inc. |
Antibodies for inhibiting blood coagulation and methods of use thereof
|
IL123756A0
(en)
*
|
1997-03-21 |
1998-10-30 |
Sankyo Co |
Humanized anti-human FAS antibody
|
US6972323B1
(en)
|
1997-04-01 |
2005-12-06 |
Sankyo Company, Limited |
Anti-Fas antibodies
|
US20020032315A1
(en)
|
1997-08-06 |
2002-03-14 |
Manuel Baca |
Anti-vegf antibodies
|
US20070059302A1
(en)
|
1997-04-07 |
2007-03-15 |
Genentech, Inc. |
Anti-vegf antibodies
|
US6884879B1
(en)
|
1997-04-07 |
2005-04-26 |
Genentech, Inc. |
Anti-VEGF antibodies
|
DE69829891T2
(de)
|
1997-04-07 |
2005-10-06 |
Genentech, Inc., South San Francisco |
Anti-VEGF Antikörper
|
PL193575B1
(pl)
|
1997-05-15 |
2007-02-28 |
Chugai Pharmaceutical Co Ltd |
Zastosowanie przeciwciała przeciwko białku pokrewnemu z hormonem przytarczyc (PTHrP)
|
EP0983303B1
(de)
|
1997-05-21 |
2006-03-08 |
Biovation Limited |
Verfahren zur herstellung von nicht-immunogenen proteinen
|
EP1019082B2
(de)
|
1997-10-02 |
2008-06-04 |
Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. |
Verwendung eines kolonie-stimulierenden faktors (csf) zum verstärken des kollateralen wachstums von kollateralen arterien und / oder anderer arterien aus bestehenden arteriolären verbindungen
|
DE69838454T2
(de)
|
1997-10-03 |
2008-02-07 |
Chugai Seiyaku K.K. |
Natürlicher menschlicher antikörper
|
TWI239847B
(en)
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
US7179892B2
(en)
|
2000-12-06 |
2007-02-20 |
Neuralab Limited |
Humanized antibodies that recognize beta amyloid peptide
|
US20080050367A1
(en)
|
1998-04-07 |
2008-02-28 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
US7964192B1
(en)
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
EP1745799B1
(de)
|
1998-03-04 |
2015-09-02 |
The Trustees of The University of Pennsylvania |
Zusammensetzungen und Verfahren zur Behandlung von Tumoren
|
US6677436B1
(en)
|
1998-04-03 |
2004-01-13 |
Chugai Seiyaku Kabushiki Kaisha |
Humanized antibody against human tissue factor (TF) and process of production of the humanized antibody
|
EP1946775A3
(de)
|
1998-08-11 |
2008-08-06 |
Biogen Idec Inc. |
Kombinationstherapien für B-Zellen-Lymphome mit Verabreichung eines Anti-CD20-Antikörpers
|
JP4689781B2
(ja)
*
|
1998-09-03 |
2011-05-25 |
独立行政法人科学技術振興機構 |
アミノ酸輸送蛋白及びその遺伝子
|
PL203114B1
(pl)
|
1998-09-14 |
2009-08-31 |
Regents Board Of |
Zastosowania przeciwciała przeciw VLA-4 lub jego fragmentu wiążącego antygen, przeciwciała przeciw integrynie alfa-4/beta7 lub jego fragmentu wiążącego antygen lub przeciwciała przeciw VCAM-1 lub jego fragmentu wiążącego antygen, zastosowania rozpuszczalnych polipeptydów VLA-4 lub VCAM-1, które antagonizują interakcję VLA-4/VCAM-1
|
AU771539C
(en)
|
1998-10-06 |
2005-01-13 |
Dyadic International (Usa), Inc. |
Transformation system in the field of filamentous fungal hosts
|
EP1939215A1
(de)
|
1998-10-22 |
2008-07-02 |
The University of Montana |
Omp85-Proteien von Neisseria Gonorrhoeae und Neisseria Meningitidis, Zusammensetzungen damit und ihre Verwendungsverfahren
|
EP1949911A3
(de)
|
1998-11-09 |
2008-08-06 |
Biogen Idec, Inc. |
Behandlung von chronischer lymphozitärer Leukämie (CLL) unter Verwendung chimärer Anti-CD20-Antikörper
|
GB9825632D0
(en)
|
1998-11-23 |
1999-01-13 |
Novartis Ag |
Organic compounds
|
US20030035798A1
(en)
|
2000-08-16 |
2003-02-20 |
Fang Fang |
Humanized antibodies
|
CA2327260A1
(en)
|
1999-03-03 |
2000-09-08 |
Biogen, Inc. |
Methods of modulating lipid metabolism and storage
|
GB9906380D0
(en)
*
|
1999-03-19 |
1999-05-12 |
Melvin William T |
Monoclonal antibodies specific for cypibi
|
NZ541431A
(en)
|
1999-04-22 |
2008-01-31 |
Biogen Idec Inc |
Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
|
IT1306704B1
(it)
|
1999-05-26 |
2001-10-02 |
Sirs Societa Italiana Per La R |
Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
|
UA81216C2
(en)
|
1999-06-01 |
2007-12-25 |
|
Prevention and treatment of amyloid disease
|
BR0011250A
(pt)
|
1999-06-01 |
2002-03-05 |
Biogen Inc |
Anticorpo monoclonal de bloqueio a vla-1 e seu uso para o tratamento de distúrbios inflamatórios
|
US7144991B2
(en)
|
1999-06-07 |
2006-12-05 |
Aletheon Pharmaceuticals, Inc. |
Streptavidin expressed gene fusions and methods of use thereof
|
US6531580B1
(en)
|
1999-06-24 |
2003-03-11 |
Ixsys, Inc. |
Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same
|
TWI255718B
(en)
|
1999-07-02 |
2006-06-01 |
Chugai Pharmaceutical Co Ltd |
Ameliorative agent for low vasopressin concentration
|
US8557244B1
(en)
|
1999-08-11 |
2013-10-15 |
Biogen Idec Inc. |
Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
|
ATE388167T1
(de)
*
|
1999-09-30 |
2008-03-15 |
Kyowa Hakko Kogyo Kk |
Menschlicher antikörper gegen gangliosid gd3 für die transplantationskomplementarität bestimmente regionund derivate des antikörpers gegen das gangliosid gd3
|
US6849425B1
(en)
|
1999-10-14 |
2005-02-01 |
Ixsys, Inc. |
Methods of optimizing antibody variable region binding affinity
|
DK1234031T3
(en)
|
1999-11-30 |
2017-07-03 |
Mayo Foundation |
B7-H1, AN UNKNOWN IMMUNE REGULATORY MOLECULE
|
EP2140881B1
(de)
|
1999-12-16 |
2013-04-17 |
Biogen Idec MA Inc. |
Verfahren zur Behandlung von ischämischen oder hämorrhagischen Traumata des Zentralnervensystems unter Verwendung von Alpha4-Integrin-Antagonisten
|
JP4992068B2
(ja)
|
2000-01-27 |
2012-08-08 |
メディミューン,エルエルシー |
超高親和性中和抗体
|
AU3327701A
(en)
*
|
2000-02-03 |
2001-08-14 |
Millennium Pharm Inc |
Humanized anti-ccr2 antibodies and methods of use therefor
|
CA2399387C
(en)
|
2000-02-11 |
2015-11-03 |
Biogen, Inc. |
Heterologous polypeptide of the tnf family
|
PL218883B1
(pl)
|
2000-02-24 |
2015-02-27 |
Lilly Co Eli |
Kompozycja farmaceutyczna zawierająca przeciwciało do zastosowania w leczeniu klinicznej lub przedklinicznej choroby Alzheimera
|
EP2341075A1
(de)
|
2000-03-01 |
2011-07-06 |
MedImmune, LLC |
Anti-rsv-f-protein-antikörper
|
EP1267926A2
(de)
|
2000-03-17 |
2003-01-02 |
Millennium Pharmaceuticals, Inc. |
Verfahren zur hemmung von stenose und restenose mit einer mischung von antikörpern gegen cd18 und ccr2
|
US20010046496A1
(en)
|
2000-04-14 |
2001-11-29 |
Brettman Lee R. |
Method of administering an antibody
|
EP1987842A1
(de)
|
2000-04-28 |
2008-11-05 |
Chugai Seiyaku Kabushiki Kaisha |
Zellproliferationshemmer
|
US7030219B2
(en)
|
2000-04-28 |
2006-04-18 |
Johns Hopkins University |
B7-DC, Dendritic cell co-stimulatory molecules
|
DE60136272D1
(de)
|
2000-04-29 |
2008-12-04 |
Univ Iowa Res Found |
Diagnostika und therapeutika für makula degeneration erkrankungen
|
TWI318983B
(en)
|
2000-05-02 |
2010-01-01 |
Uab Research Foundation |
An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
|
US7279160B2
(en)
|
2000-05-02 |
2007-10-09 |
The Uab Research Foundation |
Combinations of DR5 antibodies and other therapeutic agents
|
US7476383B2
(en)
|
2000-05-02 |
2009-01-13 |
The Uab Research Foundation |
Antibody selective for DR4 and uses thereof
|
GB0013810D0
(en)
|
2000-06-06 |
2000-07-26 |
Celltech Chiroscience Ltd |
Biological products
|
GB0020685D0
(en)
|
2000-08-22 |
2000-10-11 |
Novartis Ag |
Organic compounds
|
WO2002028905A2
(en)
|
2000-10-02 |
2002-04-11 |
Chiron Corporation |
Human anti-cd40 antibodies
|
US7179900B2
(en)
|
2000-11-28 |
2007-02-20 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
US6989247B2
(en)
|
2000-11-28 |
2006-01-24 |
Celltech R & D, Inc. |
Compositions and methods for diagnosing or treating psoriasis
|
PE20020574A1
(es)
|
2000-12-06 |
2002-07-02 |
Wyeth Corp |
Anticuerpos humanizados que reconocen el peptido amiloideo beta
|
US20040146508A1
(en)
*
|
2001-04-06 |
2004-07-29 |
Hearing Stephen David |
Use of cd25 binding molecules in steroid-resistant patients
|
AU2002258778C1
(en)
|
2001-04-13 |
2008-12-04 |
Biogen Ma Inc. |
Antibodies to VLA-1
|
US6972324B2
(en)
|
2001-05-18 |
2005-12-06 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Antibodies specific for CD44v6
|
CN1541226A
(zh)
*
|
2001-05-18 |
2004-10-27 |
���ָ��Ӣ��ķ�������Ϲ�˾ |
CD44v6特异性的抗体
|
US7541443B2
(en)
*
|
2001-06-14 |
2009-06-02 |
Tolerrx, Inc. |
Anti-CD4 antibodies
|
WO2002102973A2
(en)
|
2001-06-20 |
2002-12-27 |
Prochon Biotech Ltd. |
Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
|
US20030013081A1
(en)
|
2001-06-26 |
2003-01-16 |
Olson William C. |
Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection
|
JP4675512B2
(ja)
*
|
2001-07-10 |
2011-04-27 |
三井化学株式会社 |
熱殺菌方法
|
WO2003062370A2
(en)
|
2001-07-19 |
2003-07-31 |
Perlan Therapeutics, Inc. |
Multimeric proteins and methods of making and using same
|
JP4729717B2
(ja)
*
|
2001-08-03 |
2011-07-20 |
株式会社医学生物学研究所 |
GM1ガングリオシド結合型アミロイドβタンパク質を認識する抗体、及び該抗体をコードするDNA
|
PT1944040E
(pt)
|
2001-08-17 |
2012-10-31 |
Univ Washington |
Método de avaliação para a doença de alzheimer
|
LT1434871T
(lt)
|
2001-09-20 |
2017-04-10 |
Immunex Corporation |
Heteromerinius polipeptidus ekspresuojančių ląstelių atranka
|
CN100352844C
(zh)
|
2001-09-25 |
2007-12-05 |
财团法人化学及血清疗法研究所 |
重组抗骨桥蛋白抗体及其用途
|
GB0124317D0
(en)
|
2001-10-10 |
2001-11-28 |
Celltech R&D Ltd |
Biological products
|
US20030190705A1
(en)
*
|
2001-10-29 |
2003-10-09 |
Sunol Molecular Corporation |
Method of humanizing immune system molecules
|
CN1585778A
(zh)
*
|
2001-11-12 |
2005-02-23 |
默克专利有限公司 |
修饰的抗-TNFα抗体
|
EP1944043A1
(de)
|
2001-11-21 |
2008-07-16 |
The Trustees of the University of Pennsylvania |
Nukleinsäure- und Aminosäuresequenzen von Affen-Adenoviren, hergeleitete Vektoren und Verwendungsverfahren.
|
HU230488B1
(hu)
|
2001-11-21 |
2016-08-29 |
The Trustees Of The University Of Pennsylvania |
Simian adenovírus nukleinsav és aminosav-szekvencia, azt tartalmazó vektorok, és eljárások annak alkalmazására
|
EP2298717B1
(de)
|
2001-11-30 |
2015-10-28 |
Biogen MA Inc. |
Antikörper gegen chemotaktische Proteine
|
US7393648B2
(en)
|
2001-12-03 |
2008-07-01 |
Alexion Pharmaceuticals, Inc. |
Hybrid antibodies
|
PT1461428E
(pt)
*
|
2001-12-03 |
2012-05-29 |
Alexion Pharma Inc |
Método para produção de anticorpos híbridos
|
GB0129105D0
(en)
|
2001-12-05 |
2002-01-23 |
Celltech R&D Ltd |
Expression control using variable intergenic sequences
|
EP2295468B1
(de)
*
|
2002-02-14 |
2015-07-08 |
Immunomedics, Inc. |
Anti-CD20 Antikörper und Fusionsproteine davon und Anwendungsverfahren
|
IL163655A0
(en)
|
2002-02-22 |
2005-12-18 |
Protein Design Labs Inc |
Anti-ccr5 antibody
|
PT1485127E
(pt)
|
2002-02-25 |
2011-09-07 |
Elan Pharm Inc |
Administração de agentes para o tratamento de inflamação
|
MY139983A
(en)
|
2002-03-12 |
2009-11-30 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
BRPI0308585B8
(pt)
|
2002-03-13 |
2021-05-25 |
Biogen Idec Inc |
anticorpo isolado ou fragmento de ligação a antígeno do mesmo que se liga à alfavbeta6, composição, método de detecção in vitro de alfavbeta6 e construção de dna
|
DK1495056T3
(da)
|
2002-03-20 |
2011-05-02 |
Ucb Pharma Sa |
Fremgangsmåde til analyse af antistofdisulfidisomere
|
JP4432031B2
(ja)
|
2002-03-22 |
2010-03-17 |
ズィナイス オペレーションズ ピーティーワイ.エルティーディー. |
インターロイキン13受容体α1(IL−13Rα1)に対するモノクローナル抗体
|
GB0210121D0
(en)
|
2002-05-02 |
2002-06-12 |
Celltech R&D Ltd |
Biological products
|
US7202067B2
(en)
|
2002-05-14 |
2007-04-10 |
Martek Biosciences Corporation |
Carotene synthase gene and uses therefor
|
JP4418745B2
(ja)
|
2002-05-28 |
2010-02-24 |
ユセベ ファルマ ソシエテ アノニム |
抗体peg位置異性体、それを含む組成物及びその使用
|
EP1513554B9
(de)
*
|
2002-05-30 |
2011-11-09 |
Macrogenics, Inc. |
Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten
|
US7132100B2
(en)
|
2002-06-14 |
2006-11-07 |
Medimmune, Inc. |
Stabilized liquid anti-RSV antibody formulations
|
WO2003106485A1
(en)
|
2002-06-14 |
2003-12-24 |
Monier Tadros |
Method for the production of protamine
|
GB0213745D0
(en)
|
2002-06-14 |
2002-07-24 |
Univ Edinburgh |
Enzyme
|
WO2004002500A1
(en)
|
2002-06-28 |
2004-01-08 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Method of treating autoimmune diseases with interferon-beta and il-2r antagonist
|
WO2010011999A2
(en)
|
2008-07-25 |
2010-01-28 |
The Regents Of The University Of California |
Methods and compositions for eliciting an amyloid-selective immune response
|
US7432351B1
(en)
|
2002-10-04 |
2008-10-07 |
Mayo Foundation For Medical Education And Research |
B7-H1 variants
|
GB0228832D0
(en)
|
2002-12-10 |
2003-01-15 |
Novartis Ag |
Organic compound
|
TW200509968A
(en)
|
2002-11-01 |
2005-03-16 |
Elan Pharm Inc |
Prevention and treatment of synucleinopathic disease
|
US8506959B2
(en)
|
2002-11-01 |
2013-08-13 |
Neotope Biosciences Limited |
Prevention and treatment of synucleinopathic and amyloidogenic disease
|
ES2401136T3
(es)
|
2002-11-15 |
2013-04-17 |
Genmab A/S |
Anticuerpos monoclonales humanos contra CD25
|
CA2537263C
(en)
|
2002-11-27 |
2017-05-30 |
Minerva Biotechnologies Corporation |
Techniques and compositions for the diagnosis and treatment of cancer (muc1)
|
EP1944320A1
(de)
|
2002-12-16 |
2008-07-16 |
Genentech, Inc. |
Immunglobulinvarianten und Verwendungen davon
|
AU2004205684A1
(en)
|
2003-01-23 |
2004-08-05 |
Genentech, Inc. |
Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
|
SK50642005A3
(sk)
|
2003-01-24 |
2006-02-02 |
Elan Pharmaceuticals, Inc. |
Kompozícia na liečenie demyelizačných ochorení a paralýzy podávaním remyelizačných látok
|
EP1460088A1
(de)
*
|
2003-03-21 |
2004-09-22 |
Biotest AG |
Humanisierter Antikörper gegen CD4 mit immunsuppressiven Merkmalen
|
US7321065B2
(en)
|
2003-04-18 |
2008-01-22 |
The Regents Of The University Of California |
Thyronamine derivatives and analogs and methods of use thereof
|
ATE407698T1
(de)
|
2003-04-23 |
2008-09-15 |
Medarex Inc |
Zusammensetzungen und verfahren zur behandlung von entzündlicher darmerkrankung
|
EP2404615A1
(de)
*
|
2003-04-23 |
2012-01-11 |
Medarex, Inc. |
Humanisierte Antikörper gegen Interferon-alpha-Rezeptor-1 (IFNAR-1)
|
US7358331B2
(en)
|
2003-05-19 |
2008-04-15 |
Elan Pharmaceuticals, Inc. |
Truncated fragments of alpha-synuclein in Lewy body disease
|
HUE034320T2
(en)
|
2003-05-19 |
2018-02-28 |
Prothena Biosciences Ltd |
Truncated fragments of alpha-synuclein in lewy-body disease
|
WO2005003175A2
(en)
|
2003-06-13 |
2005-01-13 |
Biogen Idec Ma Inc. |
Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof
|
US20060162014A1
(en)
|
2003-07-07 |
2006-07-20 |
Jaffe Eileen K |
Alternate morpheeins of allosteric proteins as a target for the development of bioactive molecules
|
US8153410B2
(en)
|
2003-07-07 |
2012-04-10 |
Fox Chase Cancer Center |
Alternate morpheein forms of allosteric proteins as a target for the development of bioactive molecules
|
NZ544317A
(en)
|
2003-07-08 |
2009-05-31 |
Genentech Inc |
IL-17 A/F heterologous polypeptides and therapeutic uses thereof
|
RS53476B
(en)
|
2003-07-18 |
2014-12-31 |
Amgen Fremont Inc. |
Hepatocyte Growth Factor Binders
|
US7834155B2
(en)
|
2003-07-21 |
2010-11-16 |
Immunogen Inc. |
CA6 antigen-specific cytotoxic conjugate and methods of using the same
|
US20060228350A1
(en)
*
|
2003-08-18 |
2006-10-12 |
Medimmune, Inc. |
Framework-shuffling of antibodies
|
GB0321997D0
(en)
|
2003-09-19 |
2003-10-22 |
Novartis Ag |
Organic compound
|
CA2545166A1
(en)
*
|
2003-11-11 |
2005-05-19 |
Chugai Seiyaku Kabushiki Kaisha |
Humanized anti-cd47 antibody
|
US7361503B2
(en)
|
2003-11-12 |
2008-04-22 |
Albert Einstein College Of Medicine Of Yeshiva University |
Sequences encoding hepatitis C virus glycoproteins
|
JP4898452B2
(ja)
|
2003-12-05 |
2012-03-14 |
マルチミューン ジーエムビーエイチ |
治療および診断用抗Hsp70抗体
|
AU2004297265A1
(en)
|
2003-12-08 |
2005-06-23 |
Eisai, Inc. |
Antibodies that specifically bind PMS2
|
US20080025913A1
(en)
|
2003-12-15 |
2008-01-31 |
Bowdish Katherine S |
Novel Anti-Dc-Sign Antibodies
|
ITRM20030601A1
(it)
*
|
2003-12-24 |
2005-06-25 |
Lay Line Genomics Spa |
Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
|
RU2401277C2
(ru)
|
2004-01-07 |
2010-10-10 |
Чирон Корпорейшн |
Не мышиное анти-m-csf-антитело (варианты), его получение и использование
|
WO2005068504A1
(ja)
|
2004-01-19 |
2005-07-28 |
Medical And Biological Laboratories Co., Ltd. |
炎症性サイトカイン抑制剤
|
AU2005216013B2
(en)
|
2004-01-30 |
2010-11-11 |
Dana Farber Cancer Institute |
Method for determination and quantification of radiation or genotoxin exposure
|
EP1713503B1
(de)
|
2004-02-10 |
2013-07-31 |
The Regents of the University of Colorado, a Body Corporate |
Hemmung von faktor b, dem alternativen komplement-pfad und relevante verfahren
|
AU2005214331B2
(en)
|
2004-02-12 |
2011-09-15 |
Eisai, Inc. |
Monoclonal antibodies that specifically bind to folate receptor alpha
|
TWI359026B
(en)
|
2004-02-12 |
2012-03-01 |
Sankyo Co |
Pharmaceutical composition for the osteoclast rela
|
EP1717250A4
(de)
|
2004-02-20 |
2008-10-01 |
Immuno Biological Lab Co Ltd |
Monoklonaler antikörper und dessen verwendung
|
EP2275445A3
(de)
|
2004-03-12 |
2012-02-29 |
Vasgene Therapeutics, Inc. |
Ephb4-bindende Antikörper zur Inhibierung von Angiogenese und Tumorwachstum
|
US7625549B2
(en)
|
2004-03-19 |
2009-12-01 |
Amgen Fremont Inc. |
Determining the risk of human anti-human antibodies in transgenic mice
|
US20050260679A1
(en)
|
2004-03-19 |
2005-11-24 |
Sirid-Aimee Kellerman |
Reducing the risk of human anti-human antibodies through V gene manipulation
|
MY162179A
(en)
|
2004-04-01 |
2017-05-31 |
Elan Pharm Inc |
Steroid sparing agents and methods of using same
|
JP5223072B2
(ja)
|
2004-04-02 |
2013-06-26 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
avβ5インテグリンに関連のある疾患を治療および予防するための方法および組成物
|
EP1761784B1
(de)
|
2004-05-24 |
2016-10-26 |
Universität Zu Köln |
Identifizierung des ergothionein-transporters und therapeutische verwendungen davon
|
EP1602926A1
(de)
|
2004-06-04 |
2005-12-07 |
University of Geneva |
Neue Mittel und Verfahren zur Behandlung von Gehörverlust oder Tinnitus
|
KR101335079B1
(ko)
|
2004-06-21 |
2013-12-12 |
메다렉스, 엘.엘.시. |
인터페론 알파 수용체 1 항체 및 그의 용도
|
GB0414054D0
(en)
|
2004-06-23 |
2004-07-28 |
Owen Mumford Ltd |
Improvements relating to automatic injection devices
|
US8647625B2
(en)
|
2004-07-26 |
2014-02-11 |
Biogen Idec Ma Inc. |
Anti-CD154 antibodies
|
GB0417487D0
(en)
|
2004-08-05 |
2004-09-08 |
Novartis Ag |
Organic compound
|
EA013752B1
(ru)
|
2004-08-09 |
2010-06-30 |
Элан Фармасьютикалз, Инк. |
Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний
|
CA2478458A1
(en)
|
2004-08-20 |
2006-02-20 |
Michael Panzara |
Treatment of pediatric multiple sclerosis
|
FI20041204A0
(fi)
|
2004-09-16 |
2004-09-16 |
Riikka Lund |
Menetelmät immuunivälitteisiin sairauksiin liittyvien uusien kohdegeenien hyödyntämiseksi
|
AU2005291486A1
(en)
|
2004-10-01 |
2006-04-13 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. |
Novel antibodies directed to the mammalian EAG1 ion channel protein
|
MX2007004176A
(es)
|
2004-10-06 |
2007-06-15 |
Mayo Foundation |
B7-h1 y metodos de diagnosis, prognosis, y tratamiento de cancer.
|
SG156672A1
(en)
|
2004-10-22 |
2009-11-26 |
Amgen Inc |
Methods for refolding of recombinant antibodies
|
RU2007119382A
(ru)
|
2004-10-25 |
2008-11-27 |
Мерк энд Ко., Инк. (US) |
Антитела против addl и их применение
|
JP2008520717A
(ja)
|
2004-11-19 |
2008-06-19 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
多発性硬化症についての処置
|
CA2590337C
(en)
|
2004-12-15 |
2017-07-11 |
Neuralab Limited |
Humanized amyloid beta antibodies for use in improving cognition
|
PT1772465E
(pt)
|
2005-01-05 |
2009-05-21 |
F Star Biotech Forsch & Entw |
Domínios de imunoglobulina sintética com propriedades de ligação construídos em regiões da molécula diferentes das regiões determinantes de complementaridade
|
NZ555937A
(en)
|
2005-01-27 |
2009-05-31 |
Childrens Hosp & Res Ct Oak |
GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
|
US7745389B2
(en)
|
2005-02-14 |
2010-06-29 |
University Of Iowa Research Foundation |
Methods for treatment of age-related macular degeneration
|
CA2597945C
(en)
|
2005-02-17 |
2016-07-12 |
Biogen Idec Ma Inc. |
Treating neurological disorders
|
EP1860119B1
(de)
|
2005-02-28 |
2011-08-03 |
Institute for Antibodies Co., Ltd. |
Anti-igsf4-antikörper und dessen verwendung
|
NZ562045A
(en)
|
2005-03-02 |
2010-12-24 |
Biogen Idec Inc |
Kim-1 antibodies for treatment of TH2-mediated conditions
|
WO2006099141A2
(en)
|
2005-03-10 |
2006-09-21 |
Morphotek, Inc. |
Anti-mesothelin antibodies
|
EP1863531A1
(de)
|
2005-03-19 |
2007-12-12 |
Medical Research Council |
Verbesserungen der behandlung und prävention von virusinfektionen
|
EP2343320B1
(de)
|
2005-03-25 |
2017-10-25 |
GITR, Inc. |
Anti-gitr antikörper und ihre verwendung
|
ES2720288T3
(es)
|
2005-03-30 |
2019-07-19 |
Minerva Biotechnologies Corp |
Proliferación de células que expresan MUC1
|
WO2006105448A2
(en)
|
2005-03-30 |
2006-10-05 |
Minerva Biotechnologies Corporation |
Proliferation of muc1 expressing cells
|
EP1863519B1
(de)
|
2005-03-31 |
2013-09-25 |
The General Hospital Corporation |
Modulation von hgf/hgfr-aktivität zur behandlung von lymphödem
|
DK3264094T3
(da)
|
2005-04-04 |
2020-11-23 |
Biogen Ma Inc |
Fremgangsmåder til evaluering af en immunrespons på et terapeutisk middel
|
AU2006241099B2
(en)
|
2005-04-22 |
2012-04-19 |
Eisai, Inc. |
Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
|
CA2607455A1
(en)
|
2005-04-22 |
2006-11-02 |
Morphotek, Inc. |
Antibodies with immune effector activity and that internalize in endosialin-positive cells
|
WO2006117910A1
(ja)
|
2005-04-28 |
2006-11-09 |
Mochida Pharmaceutical Co., Ltd. |
抗血小板膜糖蛋白質ⅵモノクローナル抗体
|
WO2006117782A2
(en)
|
2005-05-04 |
2006-11-09 |
Quark Pharmaceuticals, Inc. |
Recombinant antibodies against cd55 and cd59 and uses thereof
|
EP2559690B1
(de)
|
2005-05-10 |
2016-03-30 |
Incyte Holdings Corporation |
Modulatoren von Indolamin-2,3-Dioxygenase und Verfahren zur Verwendung davon
|
CA2609038A1
(en)
|
2005-05-18 |
2006-11-23 |
Trinity Biosystems, Inc. |
Methods and compositions for immunizing against chlamydia infection
|
CA2607663C
(en)
|
2005-05-19 |
2014-08-12 |
Amgen Inc. |
Compositions and methods for increasing the stability of antibodies
|
US8911733B2
(en)
|
2005-05-26 |
2014-12-16 |
Musc Foundation For Research Development |
Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
|
PL1888113T3
(pl)
|
2005-05-27 |
2014-11-28 |
Biogen Ma Inc |
Przeciwciała wiążące TWEAK
|
US8354106B2
(en)
|
2005-06-16 |
2013-01-15 |
The Feinstein Institute For Medical Research |
Antibodies against HMGB1 and fragments thereof
|
AU2006261127B2
(en)
|
2005-06-17 |
2012-03-15 |
Merck Sharp & Dohme Corp. |
ILT3 binding molecules and uses therefor
|
PL2163562T3
(pl)
*
|
2005-06-21 |
2014-03-31 |
Xoma Us Llc |
Przeciwciała wiążące IL-1 beta i ich fragmenty
|
CN104072614B
(zh)
|
2005-07-08 |
2017-04-26 |
生物基因Ma公司 |
抗-αvβ6 抗体及其用途
|
FR2888850B1
(fr)
|
2005-07-22 |
2013-01-11 |
Pf Medicament |
Nouveaux anticorps anti-igf-ir et leurs applications
|
CA2616189C
(en)
|
2005-07-22 |
2019-03-26 |
Progenics Pharmaceuticals, Inc. |
Methods for reducing viral load in hiv-1-infected patients
|
EP2311876A3
(de)
|
2005-07-28 |
2011-04-27 |
Novartis AG |
M-CSF-spezifischer monoklonaler Antikörper und Verwendungen davon
|
US8193328B2
(en)
|
2005-09-08 |
2012-06-05 |
Philadelphia Health & Education Corporation |
Identification of modulators of serine protease inhibitor Kazal and their use as anti-cancer and anti-viral agents
|
JP2009509970A
(ja)
|
2005-09-22 |
2009-03-12 |
プロサイ インコーポレイテッド |
酵母突然変異体において産生されるグリコシル化ポリペプチドおよびその使用方法
|
WO2007051077A2
(en)
|
2005-10-28 |
2007-05-03 |
The Regents Of The University Of California |
Methods and compounds for lymphoma cell detection and isolation
|
KR20080068048A
(ko)
|
2005-10-28 |
2008-07-22 |
메이지 세이카 가부시키가이샤 |
녹농균의 외막 단백질 pa5158
|
RU2438704C2
(ru)
|
2005-11-01 |
2012-01-10 |
Эбботт Байотекнолоджи Лтд. |
Способы и композиции для диагностики анкилозирующих спондилитов с использованием биомаркеров
|
AU2006318580A1
(en)
|
2005-11-21 |
2007-05-31 |
Merck Serono Sa |
Compositions and methods of producing hybrid antigen binding molecules and uses thereof
|
SG2014013437A
(en)
|
2005-11-30 |
2014-07-30 |
Abbott Lab |
Monoclonal antibodies and uses thereof
|
DOP2006000277A
(es)
|
2005-12-12 |
2007-08-31 |
Bayer Pharmaceuticals Corp |
Anticuerpos anti mn y métodos para su utilización
|
KR20080087164A
(ko)
|
2006-01-18 |
2008-09-30 |
더 제너럴 하스피탈 코포레이션 |
림프 기능을 증가시키는 방법
|
US20080317710A1
(en)
|
2006-02-22 |
2008-12-25 |
University Of Zurich |
Methods For Treating Autoimmune or Demyelinating Diseases
|
US20070218065A1
(en)
|
2006-03-10 |
2007-09-20 |
Jaspers Stephen R |
Antibodies that bind both il-17a and il-17f and methods of using the same
|
EP2006379B1
(de)
|
2006-03-23 |
2016-08-31 |
Tohoku University |
Hochfunktioneller bispezifischer antikörper
|
CA2645904A1
(en)
|
2006-03-30 |
2007-10-11 |
Meiji Seika Kaisha, Ltd. |
Pseudomonas aeruginosa outer membrane protein pa0427
|
TWI392684B
(zh)
|
2006-04-05 |
2013-04-11 |
Abbott Biotech Ltd |
抗體之純化
|
CA2564435A1
(en)
|
2006-04-10 |
2007-10-10 |
Abbott Biotechnology Ltd. |
Methods for monitoring and treating intestinal disorders
|
EP2708242A3
(de)
|
2006-04-10 |
2014-03-26 |
Abbott Biotechnology Ltd |
Anwendungen und Zusammensetzungen zur Behandlung von Morbus Bechterew
|
WO2008063213A2
(en)
|
2006-04-10 |
2008-05-29 |
Abbott Biotechnology Ltd. |
Uses and compositions for treatment of psoriatic arthritis
|
PT2034830E
(pt)
|
2006-05-25 |
2014-10-14 |
Biogen Idec Inc |
Anticorpos anti-vla-1 para o tratamento de acidentes vasculares cerebrais
|
KR20090024748A
(ko)
|
2006-05-31 |
2009-03-09 |
아스텔라스세이야쿠 가부시키가이샤 |
인간화 항인간 오스테오폰틴 항체
|
WO2008042024A2
(en)
|
2006-06-01 |
2008-04-10 |
Elan Pharmaceuticals, Inc. |
Neuroactive fragments of app
|
WO2007144893A2
(en)
|
2006-06-15 |
2007-12-21 |
Fibron Ltd. |
Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
|
AU2007345745C1
(en)
|
2006-06-19 |
2013-05-23 |
Merck Sharp & Dohme Corp. |
ILT3 binding molecules and uses therefor
|
TWI527603B
(zh)
|
2006-06-30 |
2016-04-01 |
艾伯維生物技術有限責任公司 |
自動注射裝置
|
AT503889B1
(de)
|
2006-07-05 |
2011-12-15 |
Star Biotechnologische Forschungs Und Entwicklungsges M B H F |
Multivalente immunglobuline
|
JP2009542196A
(ja)
|
2006-07-07 |
2009-12-03 |
インターセル アーゲー |
小型の化膿連鎖球菌抗原およびそれらの使用
|
KR20090027241A
(ko)
|
2006-07-10 |
2009-03-16 |
바이오겐 아이덱 엠에이 인코포레이티드 |
Smad4-결핍 암의 성장을 억제하기 위한 조성물 및 방법
|
JP5382692B2
(ja)
|
2006-07-10 |
2014-01-08 |
学校法人藤田学園 |
抗体の分類法、抗原の同定法、抗体又は抗体セットの取得法、抗体パネルの作成法、並びに抗体又は抗体セット及びその用途
|
JP5406027B2
(ja)
|
2006-08-04 |
2014-02-05 |
ノバルティス アーゲー |
EphB3特異的抗体およびその使用
|
JP2010502573A
(ja)
|
2006-08-11 |
2010-01-28 |
ユニヴァーシティ オブ メディスン アンド デンティストリー オブ ニュー ジャージー |
二重増感剤含有ルミネッセンス化合物および結合体、ならびにその使用
|
KR20140033241A
(ko)
|
2006-08-18 |
2014-03-17 |
노바르티스 아게 |
Prlr 특이적 항체 및 그 용도
|
MY161866A
(en)
|
2006-09-13 |
2017-05-15 |
Abbvie Inc |
Cell culture improvements
|
EP2500416A1
(de)
|
2006-09-13 |
2012-09-19 |
Abbott Laboratories |
Verbesserungen an Zellkulturen
|
WO2008032833A1
(fr)
|
2006-09-14 |
2008-03-20 |
Medical & Biological Laboratories Co., Ltd. |
Anticorps présentant une activité adcc accrue et son procédé de production
|
FR2906533B1
(fr)
|
2006-09-28 |
2013-02-22 |
Pf Medicament |
Procede de generation d'anticorps actifs contre un antigene de resistance,anticorps obtenus par ledit procede et leurs utilisations
|
WO2008052796A1
(en)
|
2006-11-03 |
2008-05-08 |
U3 Pharma Gmbh |
Fgfr4 antibodies
|
CN103073641B
(zh)
|
2006-11-10 |
2015-01-21 |
株式会社立富泰克 |
在体内具有抗肿瘤活性的抗人Dlk-1抗体
|
CN103351437A
(zh)
|
2006-11-17 |
2013-10-16 |
诺瓦提斯公司 |
Lingo结合分子及其制药用途
|
EP1923069A1
(de)
|
2006-11-20 |
2008-05-21 |
Intercell AG |
Schutzpeptide gegen S. pneumoniae und diesbezügliche Zusammensetzungen, Verfahren und Verwendungen
|
US8288110B2
(en)
|
2006-12-04 |
2012-10-16 |
Perkinelmer Health Sciences, Inc. |
Biomarkers for detecting cancer
|
AU2007329307B2
(en)
|
2006-12-07 |
2012-08-02 |
Novartis Ag |
Antagonist antibodies against EphB3
|
EP2102366A4
(de)
|
2006-12-10 |
2010-01-27 |
Dyadic International Inc |
Expression und hochdurchsatz-screening komplexer exprimierter dna-bibliotheken bei fadenpilzen
|
US8440185B2
(en)
|
2006-12-26 |
2013-05-14 |
The Johns Hopkins University |
Compositions and methods for the treatment of immunologic disorders
|
AU2007339762B2
(en)
|
2006-12-27 |
2011-03-31 |
The Johns Hopkins University |
Compositions and methods for treating inflammation and auto-immune diseases
|
US7989173B2
(en)
|
2006-12-27 |
2011-08-02 |
The Johns Hopkins University |
Detection and diagnosis of inflammatory disorders
|
JP5694668B2
(ja)
|
2006-12-29 |
2015-04-01 |
ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド,ア ボディー コーポレイトTHE REGENTS OF THE UNIVERSITY OF COLORADO,a body corporate |
自己免疫疾患の診断上および治療上の標的ならびにその用途
|
EA029481B1
(ru)
|
2007-01-05 |
2018-04-30 |
Юнивэсэти Оф Цюрих |
Способ получения человеческого рекомбинантного антитела, специфично связывающего вариант эндогенного белка, формирующий аномальные патологические белковые структуры путем агрегации, олигомеризации или образования фибрилл
|
CA2675379A1
(en)
|
2007-01-12 |
2008-07-17 |
Intercell Ag |
Protective proteins of s. agalactiae, combinations thereof and methods of using the same
|
US8168415B2
(en)
|
2007-02-07 |
2012-05-01 |
The Regents Of The University Of Colorado |
Axl fusion proteins as Axl tyrosine kinase inhibitors
|
EP2130044B1
(de)
|
2007-02-16 |
2016-10-26 |
Genzyme Corporation |
Verfahren zur festestellung des risikos für schilddrüsenkrankheit
|
PL3067066T3
(pl)
|
2007-02-23 |
2019-09-30 |
Prothena Biosciences Limited |
Zapobieganie i leczenie choroby synukleinopatycznej i amyloidogennej
|
PL2118300T3
(pl)
|
2007-02-23 |
2015-11-30 |
Prothena Biosciences Ltd |
Zapobieganie i leczenie synukleinopatii i amyloidozy
|
JP2010519256A
(ja)
|
2007-02-23 |
2010-06-03 |
ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク |
免疫疾患を治療するために、HLA−E/Qa−1拘束性CD8+T細胞制御性経路を活性化または遮断する方法
|
WO2008110372A1
(en)
|
2007-03-13 |
2008-09-18 |
University Of Zurich |
Monoclonal human tumor-specific antibody
|
PL2125894T3
(pl)
|
2007-03-22 |
2019-08-30 |
Biogen Ma Inc. |
Białka wiążące, w tym przeciwciała, pochodne przeciwciał i fragmenty przeciwciał, które swoiście wiążą się z CD154 i ich zastosowania
|
AU2008237296B2
(en)
|
2007-04-05 |
2013-07-04 |
Eisai, Inc. |
Methods for inhibiting the binding of endosialin to ligands
|
WO2008134659A2
(en)
|
2007-04-27 |
2008-11-06 |
Zymogenetics, Inc. |
Antagonists to il-17a, il-17f, and il-23p19 and methods of use
|
EP2489673A3
(de)
|
2007-05-02 |
2012-09-12 |
Intercell AG |
Klebsiella-Antigene
|
WO2008143797A1
(en)
|
2007-05-11 |
2008-11-27 |
Genzyme Corporation |
Methods of producing a secreted protein
|
US7709215B2
(en)
|
2007-06-01 |
2010-05-04 |
Cytonics Corporation |
Method for diagnosing and treating acute joint injury
|
EP1997830A1
(de)
|
2007-06-01 |
2008-12-03 |
AIMM Therapeutics B.V. |
RSV-spezifische Bindemoleküle und Mittel zu ihrer Herstellung
|
EP2171451A4
(de)
|
2007-06-11 |
2011-12-07 |
Abbott Biotech Ltd |
Verfahren zur behandlung juveniler idiopathischer arthritis
|
US8613923B2
(en)
|
2007-06-12 |
2013-12-24 |
Ac Immune S.A. |
Monoclonal antibody
|
US8048420B2
(en)
|
2007-06-12 |
2011-11-01 |
Ac Immune S.A. |
Monoclonal antibody
|
JP2010529999A
(ja)
|
2007-06-14 |
2010-09-02 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
抗体製剤
|
JP2010530229A
(ja)
|
2007-06-18 |
2010-09-09 |
インターセル アーゲー |
クラミジア属の抗原
|
CN101802006B
(zh)
|
2007-06-26 |
2013-08-14 |
F-星生物技术研究与开发有限公司 |
展示结合剂
|
KR101560843B1
(ko)
|
2007-06-27 |
2015-10-15 |
고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 |
페리오스틴의 Exon-17 부위에 의해 코드되는 펩티드에 대한 항체를 함유하는 암 치료제
|
ES2591281T3
(es)
|
2007-07-12 |
2016-11-25 |
Gitr, Inc. |
Terapias de combinación que emplean moléculas de enlazamiento a GITR
|
EP2014681A1
(de)
|
2007-07-12 |
2009-01-14 |
Pierre Fabre Medicament |
Neue Antikörper zur Hemmung der C-Met-Dimerisation und Verwendungen davon
|
EP2170946A2
(de)
|
2007-07-13 |
2010-04-07 |
The Johns Hopkins University |
B7-dc-varianten
|
ES2402334T3
(es)
|
2007-08-02 |
2013-04-30 |
Gilead Biologics, Inc |
Procedimientos y composiciones para el tratamiento y el diagnóstico de la fibrosis
|
CA2698146C
(en)
|
2007-08-30 |
2016-12-20 |
Daiichi Sankyo Company, Limited |
Anti-epha2 antibody
|
WO2009031230A1
(ja)
*
|
2007-09-06 |
2009-03-12 |
Osaka University |
抗cd20モノクローナル抗体
|
EP2197893B1
(de)
|
2007-09-07 |
2013-07-24 |
Dyadic International, Inc. |
Neue pilzenzyme
|
EP2185592B1
(de)
|
2007-09-13 |
2013-01-23 |
University Of Zurich Prorektorat Forschung |
Monoklonaler amyloid-beta (abeta)-spezifischer antikörper und seine verwendung
|
MX2010002683A
(es)
|
2007-09-14 |
2010-03-26 |
Amgen Inc |
Poblaciones de anticuerpos homogeneos.
|
WO2009048539A2
(en)
|
2007-10-05 |
2009-04-16 |
Genentech, Inc. |
Monoclonal antibody
|
SG10201605897RA
(en)
|
2007-10-11 |
2016-09-29 |
Daiichi Sankyo Co Ltd |
ANTIBODY TARGETING OSTEOCLAST-RELATED PROTEIN Siglec-15
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
EP2210901A4
(de)
|
2007-10-19 |
2012-04-25 |
Immunas Pharma Inc |
Zur spezifischen bindung an ein oligomer fähiger antikörper, und dessen verwendung
|
US20100330097A1
(en)
|
2007-11-01 |
2010-12-30 |
Hageman Gregory S |
Predicting amd with snps within or near c2, factor b, plekha1, htra1, prelp, or loc387715
|
DK2207808T3
(da)
|
2007-11-02 |
2013-08-05 |
Novartis Ag |
Forbedrede Nogo-A-bindingsmolekyler samt deres farmaceutiske anvendelse
|
CA2960659C
(en)
|
2007-11-09 |
2021-07-13 |
The Salk Institute For Biological Studies |
Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors
|
ES2556214T3
(es)
|
2007-11-12 |
2016-01-14 |
U3 Pharma Gmbh |
Anticuerpos para AXL
|
SI2220241T1
(sl)
|
2007-11-28 |
2017-02-28 |
The Trustees Of The University Of Pennsylvania |
Adenovirus, ki obsega kapsidni heksonski protein opičjega E adenovirusa SAdV-39, in njegove uporabe
|
BRPI0819774A2
(pt)
|
2007-11-28 |
2014-10-14 |
Univ Pennsylvania |
Subfamília c de adenovírus sadv-40, -31 e -34 de símio e seus usos
|
EP2229410A4
(de)
|
2007-12-05 |
2012-07-04 |
Massachusetts Inst Technology |
Aglycosylierte immunglobulinmutanten
|
US8779088B2
(en)
|
2007-12-17 |
2014-07-15 |
Marfl Ab |
Vaccine for the treatment of Mycobacterium related disorders
|
CN101970468A
(zh)
|
2007-12-25 |
2011-02-09 |
明治制果株式会社 |
绿脓杆菌的ⅲ型分泌系统构成蛋白质pa1698
|
PT2237803E
(pt)
|
2007-12-28 |
2015-10-16 |
Prothena Biosciences Ltd |
Tratamento e profilaxia da amiloidose
|
CN101952316B
(zh)
|
2008-01-11 |
2015-04-01 |
亚德赫伦医疗公司 |
用于治疗炎性关节障碍的钙黏着蛋白-11 ec1结构域拮抗剂
|
AU2009203350B2
(en)
*
|
2008-01-11 |
2014-03-13 |
Gene Techno Science Co., Ltd. |
Humanized anti-alpha9 integrin antibodies and the uses thereof
|
SI2243829T1
(sl)
|
2008-01-11 |
2014-11-28 |
Astellas Pharma Inc. |
Izboljšano humanizirano anti-humano alfa9-integrinsko protitelo
|
DK2246427T3
(da)
|
2008-02-08 |
2017-02-20 |
Immunas Pharma Inc |
Antistoffer der er i stand til at binde specifikt til amyloid-beta oligomerer og anvendelse deraf
|
EP2250255A2
(de)
|
2008-03-04 |
2010-11-17 |
The Trustees of the University of Pennsylvania |
Simian-adenoviren sadv-36, -42.1, -42.2 und -44 sowie anwendungen davon
|
AU2009235622C9
(en)
|
2008-03-13 |
2015-07-02 |
Biotest Ag |
Agent for treating disease
|
JP5597553B2
(ja)
|
2008-03-13 |
2014-10-01 |
バイオテスト・アクチエンゲゼルシヤフト |
疾患治療剤
|
BRPI0909179A2
(pt)
|
2008-03-13 |
2015-08-25 |
Biotest Ag |
Composição farmacêutica, e, método de tratamento de uma doença autoimune.
|
JP5615169B2
(ja)
|
2008-03-17 |
2014-10-29 |
株式会社リブテック |
invivoで抗腫瘍活性を有する抗ヒトDlk−1抗体
|
CA2718473A1
(en)
|
2008-03-17 |
2009-09-24 |
Intercell Ag |
Peptides protective against s. pneumoniae and compositions, methods and uses relating thereto
|
AU2009226972B2
(en)
|
2008-03-17 |
2014-05-29 |
Gerhard Heusipp |
YopM as delivery vehicle for cargo molecules and as biological therapeutic for immunomodulation of inflammatory reactions
|
JPWO2009119794A1
(ja)
|
2008-03-27 |
2011-07-28 |
タカラバイオ株式会社 |
感染症予防、治療剤
|
EP2276509B1
(de)
|
2008-04-11 |
2016-06-15 |
Seattle Genetics, Inc. |
Nachweis und behandlung von bauchspeicheldrüsen-, eierstock- und anderen karzinomen
|
US8163551B2
(en)
|
2008-05-02 |
2012-04-24 |
Seattle Genetics, Inc. |
Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
|
EP2113255A1
(de)
|
2008-05-02 |
2009-11-04 |
f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. |
Zytotoxisches Immunglobulin
|
EP2300034B1
(de)
|
2008-06-02 |
2018-08-08 |
Dana-Farber Cancer Institute, Inc. |
Pharmazeutische zusammensetzung zur zur behandlung oder vorbeugung von multiplem myelom oder waldenström-makroglobulinämie
|
CA2728473A1
(en)
|
2008-06-20 |
2009-12-23 |
National University Corporation Okayama University |
Antibody against oxidized ldl/.beta.2gpi complex and use of the same
|
CA2728004C
(en)
|
2008-06-25 |
2022-05-24 |
Esbatech, An Alcon Biomedical Research Unit Llc |
Humanization of rabbit antibodies using a universal antibody framework
|
CN102164958A
(zh)
|
2008-06-25 |
2011-08-24 |
艾斯巴技术,爱尔康生物医药研究装置有限责任公司 |
使用通用抗体构架进行的兔抗体的人源化
|
ES2687259T5
(es)
|
2008-06-25 |
2022-10-14 |
Novartis Ag |
Anticuerpos estables y solubles que inhiben TNF
|
KR101927291B1
(ko)
|
2008-07-08 |
2018-12-10 |
인사이트 홀딩스 코포레이션 |
인돌아민 2,3-디옥시게나아제의 억제제로서의 1,2,5-옥사디아졸
|
WO2010008051A1
(ja)
|
2008-07-16 |
2010-01-21 |
株式会社医学生物学研究所 |
抗ヒトclcp1抗体とその用途
|
WO2010013498A1
(ja)
|
2008-08-01 |
2010-02-04 |
学校法人聖マリアンナ医科大学 |
変形性関節症治療剤又は予防剤
|
US8795981B2
(en)
|
2008-08-08 |
2014-08-05 |
Molecular Devices, Llc |
Cell detection
|
US8417011B2
(en)
|
2008-09-18 |
2013-04-09 |
Molecular Devices (New Milton) Ltd. |
Colony detection
|
EP2172485A1
(de)
|
2008-10-01 |
2010-04-07 |
Pierre Fabre Medicament |
Neuartige Anti-CXCR4-Antikörper und ihre Verwendung bei der Krebsbehandlung
|
CA2739076A1
(en)
|
2008-10-02 |
2010-04-08 |
Celtaxsys, Inc. |
Methods of modulating the negative chemotaxis of immune cells
|
US11898160B2
(en)
|
2008-10-09 |
2024-02-13 |
Minerva Biotechnologies Corporation |
Method for maintaining pluripotency in cells
|
ES2631507T3
(es)
|
2008-10-29 |
2017-08-31 |
China Synthetic Rubber Corporation |
Procedimientos y agentes para el diagnóstico y tratamiento del carcinoma hepatocelular
|
US9067981B1
(en)
|
2008-10-30 |
2015-06-30 |
Janssen Sciences Ireland Uc |
Hybrid amyloid-beta antibodies
|
JP5809978B2
(ja)
|
2008-10-31 |
2015-11-11 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
サルアデノウイルスSAdV−43、−45、−46、−47、−48、−49および−50ならびにそれらの用途
|
US9469691B2
(en)
|
2008-12-02 |
2016-10-18 |
Pierre Fabre Medicament |
Anti-cMET antibody
|
AR074439A1
(es)
|
2008-12-02 |
2011-01-19 |
Pf Medicament |
Anticuerpo anti-cmet (receptor c-met)
|
US8545839B2
(en)
|
2008-12-02 |
2013-10-01 |
Pierre Fabre Medicament |
Anti-c-Met antibody
|
EP2949666B1
(de)
|
2008-12-19 |
2018-12-19 |
Biogen International Neuroscience GmbH |
Menschliche anti-alpha-synuclein-antikörper
|
US8313915B2
(en)
|
2009-01-21 |
2012-11-20 |
Gundersen Lutheran Medical Foundation, Inc. |
Early detection of canine lyme disease by specific peptides and antibodies
|
US20100260752A1
(en)
|
2009-01-23 |
2010-10-14 |
Biosynexus Incorporated |
Opsonic and protective antibodies specific for lipoteichoic acid of gram positive bacteria
|
EP2424882A2
(de)
|
2009-02-05 |
2012-03-07 |
Intercell AG |
Gegen e.-faecalis schützende peptide, verfahren und anwendungen, die damit in zusammenhang stehen
|
EP2405938A2
(de)
|
2009-02-13 |
2012-01-18 |
Intercell AG |
Nicht typisierbare haemophilus influenza-antigene
|
WO2010096658A1
(en)
|
2009-02-19 |
2010-08-26 |
The Cleveland Clinic Foundation |
Corin as a marker for heart failure
|
CN105884903B
(zh)
|
2009-03-10 |
2019-12-06 |
贝勒研究院 |
靶向抗原呈递细胞的疫苗
|
ES2622228T3
(es)
|
2009-03-10 |
2017-07-06 |
Baylor Research Institute |
Vacunas antivíricas dirigidas a células presentadoras de antígenos
|
CN106432493B
(zh)
|
2009-03-10 |
2020-01-31 |
贝勒研究院 |
抗-cd40抗体及其用途
|
JP5725508B2
(ja)
|
2009-03-25 |
2015-05-27 |
国立大学法人東北大学 |
Lh型二重特異性抗体
|
CN102272306B
(zh)
|
2009-04-09 |
2017-12-26 |
第一三共株式会社 |
抗‑Siglec‑15抗体
|
WO2010118435A2
(en)
|
2009-04-10 |
2010-10-14 |
Tufts Medical Center, Inc. |
Par-1 activation by metalloproteinase-1 (mmp-1)
|
EP2419447B1
(de)
|
2009-04-17 |
2017-08-23 |
Immunas Pharma, Inc. |
Spezifisch an abeta-oligmomere bindende antikörper und ihre verwendung
|
MX2011011541A
(es)
|
2009-04-29 |
2012-02-28 |
Abbott Biotech Ltd |
Dispositivo de inyeccion automatico.
|
EP2246364A1
(de)
|
2009-04-29 |
2010-11-03 |
Pierre Fabre Médicament |
Antikörper gegen CXCR4 zur Behandlung von HIV
|
EP2270053A1
(de)
|
2009-05-11 |
2011-01-05 |
U3 Pharma GmbH |
Humanisierte AXL-Antikörper
|
WO2010138675A1
(en)
|
2009-05-29 |
2010-12-02 |
The Trustees Of The University Of Pennsylvania |
Simian adenovirus 41 and uses thereof
|
EP2260864A1
(de)
|
2009-06-10 |
2010-12-15 |
University of Melbourne |
Therapeutische Anwendungen
|
TWI513465B
(zh)
|
2009-06-25 |
2015-12-21 |
Regeneron Pharma |
以dll4拮抗劑與化學治療劑治療癌症之方法
|
EP2456460A4
(de)
|
2009-07-24 |
2013-02-20 |
Univ California |
Verfahren und zusammensetzungen zur behandlung und prävention von mit avb5-integrin assoziierten krankheiten
|
SG177763A1
(en)
|
2009-07-28 |
2012-03-29 |
Hoffmann La Roche |
Non-invasive in vivo optical imaging method
|
AU2010280981B2
(en)
|
2009-08-05 |
2016-01-28 |
Nexigen Gmbh |
Human HCV-interacting proteins and methods of use
|
WO2011024114A1
(en)
|
2009-08-25 |
2011-03-03 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Targeting extracellular matrix molecules for the treatment of cancer
|
TWI412375B
(zh)
|
2009-08-28 |
2013-10-21 |
Roche Glycart Ag |
人類化抗cdcp1抗體
|
IN2012DN02753A
(de)
|
2009-08-31 |
2015-09-18 |
Amplimmune Inc |
|
WO2011032119A1
(en)
|
2009-09-14 |
2011-03-17 |
The Regents Of The University Of Colorado |
Modulation of yeast-based immunotherapy products and responses
|
EP2305285A1
(de)
|
2009-09-29 |
2011-04-06 |
Julius-Maximilians-Universität Würzburg |
Mittel und Verfahren zur Behandlung von ischämischen Erkrankungen
|
US8568726B2
(en)
|
2009-10-06 |
2013-10-29 |
Medimmune Limited |
RSV specific binding molecule
|
EP2308897A1
(de)
|
2009-10-09 |
2011-04-13 |
Pierre Fabre Medicament |
Chimäre Antikörper spezifisch für CD151 und deren Verwendung zur Behandlung von Krebs
|
AU2010303156B2
(en)
|
2009-10-11 |
2016-02-04 |
Biogen Ma Inc. |
Anti-VLA-4 related assays
|
JP5818003B2
(ja)
|
2009-11-18 |
2015-11-18 |
国立大学法人東北大学 |
ヒト型化抗egfr抗体可変領域の高機能性変異体
|
EP2332929A1
(de)
|
2009-11-25 |
2011-06-15 |
ArisGen SA |
Orthoester-Derivate aus Kronenäthern als Träger für diagnostische und pharmazeutische Zusammensetzungen
|
GB0920944D0
(en)
|
2009-11-30 |
2010-01-13 |
Biotest Ag |
Agents for treating disease
|
WO2011068870A2
(en)
|
2009-12-01 |
2011-06-09 |
President And Fellows Of Harvard College |
Modulation of nk cell antigen specific effector activity by modulation of cxcr6 (cd186)
|
US20110150891A1
(en)
|
2009-12-16 |
2011-06-23 |
Philip Bosch |
Methods of Treating Interstitial Cystitis
|
WO2011088193A2
(en)
|
2010-01-13 |
2011-07-21 |
University Of Medicine And Dentistry Of New Jersey |
Fluorophore chelated lanthanide luminiscent probes with improved quantum efficiency
|
CA2787783A1
(en)
|
2010-01-20 |
2011-07-28 |
Tolerx, Inc. |
Anti-ilt5 antibodies and ilt5-binding antibody fragments
|
JP5947727B2
(ja)
|
2010-01-20 |
2016-07-06 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
抗ilt5抗体およびilt5結合抗体断片による免疫調節
|
US20130011407A1
(en)
|
2010-01-29 |
2013-01-10 |
Axis Inc. |
Pharmaceutical composition for treatment or prevention of osteoarthritis, and method of production therefor
|
CN102821786B
(zh)
|
2010-01-29 |
2016-01-13 |
阿克西斯股份有限公司 |
含有骨关节炎治疗剂的注射液
|
JP2012246222A
(ja)
|
2010-01-29 |
2012-12-13 |
Axis Inc |
変形性関節症治療剤または予防剤を製造するための使用
|
EP2531613A2
(de)
|
2010-02-02 |
2012-12-12 |
Abbott Biotechnology Ltd. |
Verfahren und zusammensetzungen zur prognose des ansprechens auf eine behandlung mit einem tnf-alpha-hemmer
|
AU2011213609B2
(en)
|
2010-02-08 |
2016-11-03 |
Agensys, Inc. |
Antibody drug conjugates (ADC) that bind to 161P2F10B proteins
|
CN105315370A
(zh)
|
2010-02-18 |
2016-02-10 |
加利福尼亚大学董事会 |
整合素αVβ8中和抗体
|
WO2011109398A2
(en)
|
2010-03-02 |
2011-09-09 |
President And Fellows Of Harvard College |
Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
|
AU2011223456A1
(en)
|
2010-03-03 |
2012-10-18 |
The University Of British Columbia |
Oligomer-specific amyloid beta epitope and antibodies
|
AU2011231558B2
(en)
|
2010-03-26 |
2016-08-11 |
Westfaelische Wilhelms-Universitaet Muenster |
Substitute therapy for glucocorticoids
|
EP2371863A1
(de)
|
2010-03-30 |
2011-10-05 |
Pierre Fabre Médicament |
Menschlische Antikörper gegen CXCR4 zur Behandlung von Krebs
|
DK2556090T3
(en)
|
2010-04-09 |
2016-05-30 |
Critical Care Diagnostics Inc |
Soluble, human st-2 antibodies and assays
|
EP2558499B1
(de)
|
2010-04-16 |
2017-04-12 |
Biogen MA Inc. |
Antikörper gegen vla-4
|
CN104906656B
(zh)
|
2010-04-21 |
2020-01-10 |
艾伯维生物技术有限公司 |
用于治疗药剂的受控输送的可佩戴自动注射装置
|
WO2011138462A1
(en)
|
2010-05-07 |
2011-11-10 |
F. Hoffmann-La Roche Ag |
Diagnostic method for the detection of cells ex vivo
|
KR101624381B1
(ko)
|
2010-05-17 |
2016-05-25 |
가부시키가이샤 리부텍쿠 |
in vivo 에서 항종양 활성을 갖는 항인간 TROP-2 항체
|
WO2011146727A1
(en)
|
2010-05-19 |
2011-11-24 |
Philip Bosch |
Methods of treating interstitial cystitis
|
WO2012005076A1
(ja)
|
2010-07-08 |
2012-01-12 |
本田技研工業株式会社 |
高周波加熱用コイル
|
BR112013000796B1
(pt)
|
2010-07-14 |
2021-08-31 |
Merck Sharp & Dohme Corp |
Anticorpo isolado ou um fragmento de ligação ao antígeno, composição farmacêutica, métodos para inibir a montagem de ligantes difusíveis derivados de ß-amiloide, para inibir a fosforilação de proteína tau em ser202/thr205, para identificar um suposto agente terapêutico, para detectar ligantes difusíveis derivados de ß-amiloide e para diagnosticar uma doença associada aos ligantes difusíveis derivados de ß-amiloide, e, kit para detectar ligantes difusíveis derivados de ß-amiloide
|
AU2011279044B2
(en)
|
2010-07-15 |
2013-12-19 |
Adheron Therapeutics, Inc. |
Humanized antibodies targeting the EC1 domain of Cadherin-11 and related compositions and methods
|
MX360097B
(es)
|
2010-07-29 |
2018-10-22 |
Eleven Biotherapeutics Inc |
Agonistas y antagonistas del receptor tipo i de il-1 quimérico.
|
KR101713365B1
(ko)
|
2010-07-30 |
2017-03-08 |
에이씨 이뮨 에스.에이. |
안전하고 기능적인 인간화 항 베타-아밀로이드 항체
|
JP2012034668A
(ja)
|
2010-08-12 |
2012-02-23 |
Tohoku Univ |
ヒト型化抗egfr抗体リジン置換可変領域断片及びその利用
|
WO2012027494A1
(en)
|
2010-08-24 |
2012-03-01 |
Regents Of The University Of Minnesota |
Bispecific targeting reagents
|
WO2012025636A1
(en)
|
2010-08-27 |
2012-03-01 |
University Of Zurich |
Method for target and drug validation in inflammatory and/or cardiovascular diseases
|
JP2013540991A
(ja)
|
2010-08-27 |
2013-11-07 |
ユニバーシティ・オブ・チューリッヒ |
炎症および/または心血管疾患における新規診断および治療標的
|
WO2012028697A1
(en)
|
2010-09-01 |
2012-03-08 |
Eth Zürich, Institute Of Molecular Biology And Biophysics |
Affinity purification system based on donor strand complementation
|
US20120244141A1
(en)
|
2010-09-28 |
2012-09-27 |
Boehringer Ingelheim International Gmbh |
Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
|
US8497138B2
(en)
|
2010-09-30 |
2013-07-30 |
Genetix Limited |
Method for cell selection
|
US9675693B2
(en)
|
2010-09-30 |
2017-06-13 |
Riken |
Methods and drugs targeting Eva1 or Ceacam1 gene expression for treatment and diagnosing of glioma
|
ES2686550T3
(es)
|
2010-10-11 |
2018-10-18 |
Biogen International Neuroscience Gmbh |
Anticuerpos anti-tau humanos
|
RU2600444C2
(ru)
|
2010-10-13 |
2016-10-20 |
Янссен Байотек, Инк. |
Человеческие антитела к онкостатину м и способы их применения
|
EP2630160B1
(de)
|
2010-10-18 |
2016-11-09 |
MediaPharma S.r.l. |
Erbb3-bindender antikörper
|
UY33679A
(es)
|
2010-10-22 |
2012-03-30 |
Esbatech |
Anticuerpos estables y solubles
|
ES2730941T7
(es)
|
2010-10-22 |
2020-05-27 |
Seattle Genetics Inc |
Efectos sinérgicos entre los conjugados de conjugados anticuerpo-fármaco a base de auristatina e inhibidores de la ruta PI3K-AKT-mTOR
|
LT3326645T
(lt)
|
2010-10-25 |
2020-08-10 |
Biogen Ma Inc. |
Alfa-4 integrino aktyvumo skirtumų, koreliuojant su skirtumais svcam ir (arba) smadcam lygiuose, nustatymo būdai
|
CN103180342A
(zh)
|
2010-10-27 |
2013-06-26 |
皮埃尔法布雷医药公司 |
用于治疗hiv的抗体
|
SI2636736T1
(sl)
|
2010-10-29 |
2016-09-30 |
Daiichi Sankyo Company, Limited |
Novo anti-dr5 protitelesce
|
WO2012068463A2
(en)
|
2010-11-18 |
2012-05-24 |
Beth Israel Deaconess Medicall Center, Inc. |
Methods of treating obesity by inhibiting nicotinamide n-methyl transferase (nnmt)
|
KR101919170B1
(ko)
|
2010-11-19 |
2018-11-15 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
중화 항-ccl20 항체
|
EP2643465B1
(de)
|
2010-11-23 |
2016-05-11 |
The Trustees Of The University Of Pennsylvania |
Affen-adenovirus a1321 der subfamilie e und verwendungen davon
|
EP3628689A1
(de)
|
2010-12-17 |
2020-04-01 |
Neurimmune Holding AG |
Humane anti-sod1 antikörper
|
US9085772B2
(en)
|
2010-12-27 |
2015-07-21 |
National University Corporation Nagoya University |
Method for suppressing receptor tyrosine kinase-mediated pro-survival signaling in cancer cell
|
WO2012095412A1
(en)
|
2011-01-10 |
2012-07-19 |
Ct Atlantic Ltd. |
Combination therapy including tumor associated antigen binding antibodies
|
DK3252076T3
(da)
|
2011-01-14 |
2019-12-02 |
Univ California |
Diagnostisk anvendelse af antistoffer mod ror-1-protein
|
EP2667918B1
(de)
|
2011-01-24 |
2017-03-01 |
AbbVie Biotechnology Ltd |
Automatische injektionsvorrichtungen mit übersrpitzten griffflächen
|
WO2012104824A1
(en)
|
2011-02-04 |
2012-08-09 |
Ecole polytechnique fédérale de Lausanne (EPFL) |
Therapeutic antibodies targeting app-c99
|
WO2012107589A1
(en)
|
2011-02-11 |
2012-08-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
|
WO2012110843A1
(en)
|
2011-02-18 |
2012-08-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for promoting fibrinolysis and thrombolysis
|
WO2012113775A1
(en)
|
2011-02-21 |
2012-08-30 |
University Of Zurich |
Ankyrin g and modulators thereof for the treatment of neurodegenerative disorders
|
JP6385060B2
(ja)
|
2011-03-07 |
2018-09-05 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
治療的に活性な抗体のインビボにおける選択
|
JP6100704B2
(ja)
|
2011-03-07 |
2017-03-22 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
治療用抗体についてのインビボ試験の手段および方法
|
WO2012120130A1
(en)
|
2011-03-09 |
2012-09-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods to characterize patients suffering from hemolysis
|
WO2012125680A1
(en)
|
2011-03-16 |
2012-09-20 |
Novartis Ag |
Methods of treating vasculitis using an il-17 binding molecule
|
EP2686417B1
(de)
|
2011-03-17 |
2016-06-08 |
Miltenyi Biotec GmbH |
Tcralpha/beta-depletierte zellpräparationen
|
TW201300418A
(zh)
|
2011-03-25 |
2013-01-01 |
Baylor Res Inst |
用於抗c型肝炎病毒免疫之組合物及方法
|
TW201249867A
(en)
|
2011-04-01 |
2012-12-16 |
Astellas Pharma Inc |
Novel anti-human il-23 receptor antibody
|
CN107096098A
(zh)
|
2011-04-21 |
2017-08-29 |
艾伯维公司 |
可佩戴式自动注射装置
|
CA2834136C
(en)
|
2011-04-25 |
2018-04-17 |
Daiichi Sankyo Company, Limited |
Anti-b7-h3 antibody
|
KR20230021758A
(ko)
|
2011-05-02 |
2023-02-14 |
밀레니엄 파머슈티컬스 인코퍼레이티드 |
항-α4β7 항체에 대한 제형
|
UA116189C2
(uk)
|
2011-05-02 |
2018-02-26 |
Мілленніум Фармасьютікалз, Інк. |
КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
|
UA117218C2
(uk)
|
2011-05-05 |
2018-07-10 |
Мерк Патент Гмбх |
Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
|
EP2707711A1
(de)
|
2011-05-09 |
2014-03-19 |
The Cleveland Clinic Foundation |
Serum s100b und verwendungen davon
|
WO2012163848A1
(en)
|
2011-05-27 |
2012-12-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of crohn's disease
|
EP2530088A1
(de)
|
2011-05-30 |
2012-12-05 |
Klinikum rechts der Isar der Technischen Universität München |
Mittel und Verfahren zur Diagnose und Behandlung von Multipler Sklerose
|
US20140186363A1
(en)
|
2011-06-03 |
2014-07-03 |
University Of Zurich |
Magea3 binding antibodies
|
JP2014518889A
(ja)
|
2011-06-03 |
2014-08-07 |
シーティー アトランティック リミテッド |
Magea3結合抗体
|
WO2012170071A1
(en)
|
2011-06-06 |
2012-12-13 |
Elan Pharmaceuticas, Inc |
Mcam antagonists and methods of treatment
|
WO2012172449A1
(en)
|
2011-06-13 |
2012-12-20 |
Pfizer Inc. |
Lactams as beta secretase inhibitors
|
US20140120555A1
(en)
|
2011-06-20 |
2014-05-01 |
Pierre Fabre Medicament |
Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
|
AU2012272790B2
(en)
|
2011-06-23 |
2016-10-06 |
Biogen International Neuroscience Gmbh |
Anti-alpha synuclein binding molecules
|
DE202011103324U1
(de)
|
2011-07-12 |
2012-01-02 |
Nekonal S.A.R.L. |
Therapeutische anti-TIRC7 Antikörper für die Verwendung in Immun und anderen Krankheiten
|
GB201112056D0
(en)
|
2011-07-14 |
2011-08-31 |
Univ Leuven Kath |
Antibodies
|
US20140308275A1
(en)
|
2011-07-27 |
2014-10-16 |
Inserm (Institut National De La Sante Et De La Recherche Medicale |
Methods for diagnosing and treating myhre syndrome
|
RS56876B1
(sr)
|
2011-08-11 |
2018-04-30 |
Astellas Pharma Inc |
Novo antitelo protiv humanog ngf
|
WO2013024517A1
(ja)
|
2011-08-12 |
2013-02-21 |
国立感染症研究所 |
アスペルギルス フミガーツス感染症の検査、予防及び治療のための方法並びに組成物
|
US20140271680A1
(en)
|
2011-08-12 |
2014-09-18 |
Universite Paris-Est Creteil Val De Marne |
Methods and pharmaceutical compositions for treatment of pulmonary hypertension
|
GB201116092D0
(en)
|
2011-09-16 |
2011-11-02 |
Bioceros B V |
Antibodies and uses thereof
|
UA115657C2
(uk)
|
2011-09-19 |
2017-12-11 |
Аксон Ньюросайєнс Сє |
Виділене антитіло, яке зв'язується з одним або декількома епітопами тау, фармацевтична композиція, що його містить, спосіб лікування та спосіб діагностики хвороби альцгеймера на основі виділеного антитіла
|
GB2495115A
(en)
*
|
2011-09-29 |
2013-04-03 |
Oxford Plastic Sys Ltd |
Base for supporting temporary fence panels or posts.
|
TW201329105A
(zh)
|
2011-10-04 |
2013-07-16 |
Thr Trustees Of Columbia University In The City Of New York |
人類notch1引誘物
|
WO2013050540A1
(en)
|
2011-10-05 |
2013-04-11 |
University Of Bremen |
Wnt4 and med12 for use in the diagnosis and treatment of tumor diseases
|
WO2013050441A1
(en)
|
2011-10-05 |
2013-04-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for inhibiting or preventing platelet aggregation
|
WO2013054320A1
(en)
|
2011-10-11 |
2013-04-18 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
|
US10378060B2
(en)
|
2011-10-14 |
2019-08-13 |
Dana-Farber Cancer Institute, Inc. |
ZNF365/ZFP365 biomarker predictive of anti-cancer response
|
CN109456932A
(zh)
|
2011-10-17 |
2019-03-12 |
米纳瓦生物技术公司 |
用于干细胞增殖和诱导的培养基
|
US20140248284A1
(en)
|
2011-10-20 |
2014-09-04 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods for the detection and the treatment of cardiac remodeling
|
EP2589609A1
(de)
|
2011-11-03 |
2013-05-08 |
Pierre Fabre Medicament |
Antigenbindendes Protein und dessen Verwendung als Adressierungsprodukt bei der Behandlung von Krebs
|
US9427464B2
(en)
|
2011-11-22 |
2016-08-30 |
Chiome Bioscience Inc. |
Anti-human TROP-2 antibody having an antitumor activity in vivo
|
CN103998466A
(zh)
|
2011-11-22 |
2014-08-20 |
国家医疗保健研究所 |
用于降低气道高反应的方法和药物组合物
|
WO2013079487A1
(en)
|
2011-11-28 |
2013-06-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Pharmaceutical composition for use in the treatment of dysfunction associated with aging
|
EP2602621A1
(de)
|
2011-12-08 |
2013-06-12 |
Julius-Maximilians-Universität Würzburg |
LASP-1, neuer Harnmarker zur Erkennung eines Übergangszellenkarzinoms
|
RU2658438C2
(ru)
*
|
2011-12-13 |
2018-06-21 |
Нордик Нановектор Аса |
Химерное терапевтическое антитело нн1 против cd-37
|
WO2013093122A2
(en)
|
2011-12-23 |
2013-06-27 |
Phenoquest Ag |
Antibodies for the treatment and diagnosis of affective and anxiety disorders
|
FR2984750B1
(fr)
|
2011-12-23 |
2014-01-10 |
Lfb Biotechnologies |
Nouvelles compositions pharmaceutiques comprenant un anticorps liant le recepteur humain de l'hormone anti-mullerienne de type ii
|
CA2861793C
(en)
|
2011-12-28 |
2023-08-01 |
Immunoqure Ag |
Method of providing monoclonal auto-antibodies with desired specificity
|
SG11201403756PA
(en)
|
2012-01-01 |
2014-11-27 |
Qbi Entpr Ltd |
Endo180-targeted particles for selective delivery of therapeutic and diagnostic agents
|
CN104254778A
(zh)
|
2012-02-10 |
2014-12-31 |
西雅图遗传学公司 |
Cd30+癌症的检测和治疗
|
AU2013221635B2
(en)
|
2012-02-16 |
2017-12-07 |
Santarus, Inc. |
Anti-VLA1 (CD49a) antibody pharmaceutical compositions
|
IN2014KN01772A
(de)
|
2012-02-23 |
2015-10-23 |
U3 Pharma Gmbh |
|
US9371391B2
(en)
|
2012-02-28 |
2016-06-21 |
Astellas Pharma Inc. |
Anti-human IL-23 receptor antibody and encoding polynucleotides
|
UA121844C2
(uk)
|
2012-03-15 |
2020-08-10 |
Янссен Байотек, Інк. |
Людське антитіло до cd27, спосіб його одержання та застосування
|
TR201909801T4
(tr)
|
2012-03-20 |
2019-07-22 |
Biogen Ma Inc |
JCV nötrleştirici antikorlar.
|
MX2014011826A
(es)
|
2012-03-30 |
2014-11-21 |
Daiichi Sankyo Co Ltd |
Anticuerpo anti-siglec-15 novedoso.
|
WO2013147213A1
(ja)
|
2012-03-30 |
2013-10-03 |
第一三共株式会社 |
CDR改変抗Siglec-15抗体
|
EP2833900B1
(de)
|
2012-04-01 |
2018-09-19 |
Technion Research & Development Foundation Limited |
Extrazelluläre matrix-metalloproteasen-induktor (emmprin)-peptide und bindende antikörper
|
CN103382223B
(zh)
|
2012-04-01 |
2015-06-10 |
上海益杰生物技术有限公司 |
针对表皮生长因子受体隐蔽表位和t细胞抗原的多功能抗体多肽
|
MX2014011849A
(es)
|
2012-04-02 |
2015-04-08 |
Gundersen Lutheran Health System Inc |
Reactivos, procedimientos y kits para la clasificación del cáncer.
|
JP6188681B2
(ja)
|
2012-04-09 |
2017-08-30 |
第一三共株式会社 |
抗fgfr2抗体
|
EP2841457B1
(de)
|
2012-04-27 |
2019-04-24 |
Daiichi Sankyo Company, Limited |
Anti-robo4-antikörper
|
US9062120B2
(en)
|
2012-05-02 |
2015-06-23 |
Janssen Biotech, Inc. |
Binding proteins having tethered light chains
|
US9416189B2
(en)
|
2012-05-11 |
2016-08-16 |
Microbial Chemistry Research Foundation |
Anti-CXADR antibody
|
MX362497B
(es)
|
2012-05-15 |
2019-01-21 |
Eisai Inc |
Un anticuerpo que se une específicamente al receptor alfa del folato y usos del mismo.
|
SG11201407343XA
(en)
|
2012-05-18 |
2014-12-30 |
Univ Pennsylvania |
Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof
|
EP2852679A1
(de)
|
2012-05-22 |
2015-04-01 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Verfahren zur diagnose und behandlung von fokal segmentaler glomerulosklerose
|
CN104603149B
(zh)
|
2012-05-24 |
2017-06-30 |
万机集团有限公司 |
与预防和治疗狂犬病感染相关的组合物和方法
|
LT3338794T
(lt)
|
2012-07-13 |
2020-05-25 |
The Trustees Of The University Of Pennsylvania |
Car priešnavikinio aktyvumo toksiškumo reguliavimas
|
PL2875049T3
(pl)
|
2012-07-18 |
2019-07-31 |
Institut National De La Santé Et De La Recherche Médicale (Inserm) |
Sposoby zapobiegania i leczenia przewlekłej choroby nerek (ckd)
|
EP3539563A1
(de)
|
2012-07-19 |
2019-09-18 |
Redwood Bioscience, Inc. |
Für cd22 spezifischer antikörper und verfahren zur verwendung davon
|
WO2014021339A1
(ja)
|
2012-07-30 |
2014-02-06 |
国立大学法人名古屋大学 |
ヒトミッドカインに対するモノクローナル抗体
|
CN109369808B
(zh)
|
2012-08-24 |
2023-11-07 |
加利福尼亚大学董事会 |
用于治疗ror1癌症并抑制转移的抗体和疫苗
|
TWI660972B
(zh)
|
2012-09-10 |
2019-06-01 |
愛爾蘭商尼歐托普生物科學公司 |
抗mcam抗體及相關使用方法
|
AU2013316441B2
(en)
|
2012-09-13 |
2018-08-09 |
Chugai Seiyaku Kabushiki Kaisha |
Gene knock-in non-human animal
|
EP2711016A1
(de)
|
2012-09-21 |
2014-03-26 |
Covagen AG |
Neue IL-17A-Verbindungsmoleküle und medizinische Verwendungen davon
|
LT2905335T
(lt)
|
2012-10-03 |
2018-04-10 |
Chiome Bioscience Inc. |
Antikūnas prieš žmogaus dlk-1, pasižymintis priešnavikiniu aktyvumu in vivo sąlygomis
|
CA2886120A1
(en)
|
2012-10-08 |
2014-04-17 |
St. Jude Children's Research Hospital |
Therapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis
|
BR122021014365B1
(pt)
|
2012-10-11 |
2022-07-05 |
Daiichi Sankyo Company, Limited |
Conjugado de anticorpo-fármaco, fármacos e composição farmacêutica compreendendo os mesmos, e uso
|
DE102012020496A1
(de)
|
2012-10-18 |
2014-04-24 |
Charité - Universitätsmedizin Berlin |
Biomarker zur Diagnostik und Behandlung von Neurofibromatose Typ 1
|
WO2014061277A1
(ja)
|
2012-10-19 |
2014-04-24 |
第一三共株式会社 |
親水性構造を含むリンカーで結合させた抗体-薬物コンジュゲート
|
EP2911681A1
(de)
|
2012-10-26 |
2015-09-02 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Lyve-1-antagonisten zur vorbeugung oder behandlung eines pathologischen leidens in zusammenhang mit lymphangiogenese
|
US10189906B2
(en)
|
2012-11-01 |
2019-01-29 |
Max-Delrück-Centrum Für Molekulare Medizin |
Antibody that binds CD269 (BCMA) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
|
AR093357A1
(es)
|
2012-11-05 |
2015-06-03 |
Pf Medicament |
Proteinas de union al antigeno y su utilizacion como producto de direccionamiento para el tratamiento del cancer
|
WO2014072416A1
(en)
|
2012-11-08 |
2014-05-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of bone metastases
|
AR093445A1
(es)
|
2012-11-14 |
2015-06-10 |
Regeneron Pharma |
Metodos para tratar el cancer de ovario con antagonistas de dll4
|
RS60084B1
(sr)
|
2012-12-10 |
2020-05-29 |
Biogen Ma Inc |
Antitela anti-antigen 2 dendritske ćelije krvi i njihove upotrebe
|
US20160185847A1
(en)
|
2012-12-17 |
2016-06-30 |
Laboratoire Francais Du Fractionnement Et Des Biotechnologies |
Use of monoclonal antibodies for the treatment of inflammation and bacterial infections
|
WO2014100602A1
(en)
|
2012-12-20 |
2014-06-26 |
Hospital For Special Surgery |
Treatment of egf-receptor dependent pathologies
|
ES2816700T3
(es)
|
2012-12-21 |
2021-04-05 |
Biogen Ma Inc |
Anticuerpos anti-tau humanos
|
CA2896824A1
(en)
|
2012-12-31 |
2014-07-03 |
Neurimmune Holding Ag |
Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases
|
EP2752426A1
(de)
|
2013-01-03 |
2014-07-09 |
Covagen AG |
Humane Serumalbumin bindende Verbindungen und Fusionsproteine daraus
|
BR112015018035A2
(pt)
|
2013-01-28 |
2017-11-21 |
Evec Inc |
anticorpo anti-hmgb1 humanizado ou seu fragmento que se liga ao antígeno
|
WO2014118317A1
(en)
|
2013-02-01 |
2014-08-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting and preventing metastasis in triple negative breast cancers
|
JP6357113B2
(ja)
|
2013-02-08 |
2018-07-11 |
株式会社医学生物学研究所 |
ヒトnrg1タンパク質に対する抗体
|
RU2015139095A
(ru)
|
2013-02-15 |
2017-03-21 |
ИЭсБиЭйТЕК - Э НОВАРТИС КОМПАНИ ЭлЭлСи |
Акцепторный каркасный участок для пересадки cdr
|
RU2015139890A
(ru)
|
2013-02-20 |
2017-03-27 |
ИЭсБиЭйТЕК - Э НОВАРТИС КОМПАНИ ЭлЭлСи |
Акцепторный каркасный участок для пересадки cdr
|
FR3004184B1
(fr)
|
2013-02-26 |
2016-03-18 |
Agronomique Inst Nat Rech |
Anticorps anti-gluten desamide et utilisations.
|
ES2673583T3
(es)
|
2013-02-28 |
2018-06-22 |
National Cancer Center |
Anticuerpo contra fibrina insoluble
|
ES2811060T3
(es)
|
2013-03-08 |
2021-03-10 |
Univ Osaka |
Anticuerpo contra péptido codificado por exón-21 de periostina y composición farmacéutica para prevenir o tratar enfermedades asociadas a inflamación que contienen el mismo
|
US10023608B1
(en)
|
2013-03-13 |
2018-07-17 |
Amgen Inc. |
Protein purification methods to remove impurities
|
WO2014160371A1
(en)
|
2013-03-13 |
2014-10-02 |
Eleven Biotherapeutics, Inc. |
Chimeric cytokine formulations for ocular delivery
|
US9302005B2
(en)
|
2013-03-14 |
2016-04-05 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
US10081673B2
(en)
|
2013-03-14 |
2018-09-25 |
Ffe Therapeutics Llc |
Compositions and methods for treating angiogenesis-related disorders
|
US10035860B2
(en)
|
2013-03-15 |
2018-07-31 |
Biogen Ma Inc. |
Anti-alpha V beta 6 antibodies and uses thereof
|
JP2016515120A
(ja)
|
2013-03-15 |
2016-05-26 |
バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. |
抗アルファvベータ5抗体を用いた急性腎損傷の治療及び予防
|
US10035859B2
(en)
|
2013-03-15 |
2018-07-31 |
Biogen Ma Inc. |
Anti-alpha V beta 6 antibodies and uses thereof
|
NZ712903A
(en)
|
2013-03-18 |
2018-07-27 |
Biocerox Prod Bv |
Humanized anti-cd134 (ox40) antibodies and uses thereof
|
ES2823648T3
(es)
|
2013-04-01 |
2021-05-07 |
Univ California |
Métodos y composiciones para tratar y prevenir enfermedades asociadas con la integrina AVB8
|
WO2014174596A1
(ja)
|
2013-04-23 |
2014-10-30 |
株式会社医学生物学研究所 |
ヘパリン結合上皮増殖因子様増殖因子に対する機能性モノクローナル抗体
|
US9717648B2
(en)
|
2013-04-24 |
2017-08-01 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
CN107460201A
(zh)
|
2013-05-08 |
2017-12-12 |
科济生物医药(上海)有限公司 |
编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞
|
WO2014205374A1
(en)
|
2013-06-20 |
2014-12-24 |
The Trustees Of The University Of Pennsylvania |
Methods for diagnosing pancreatic cancer
|
ES2911663T3
(es)
|
2013-07-03 |
2022-05-20 |
Immunoqure Ag |
Anticuerpos humanos anti-IFN-alfa
|
WO2015001082A1
(en)
|
2013-07-05 |
2015-01-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Novel alternative splice transcripts for mhc class i related chain alpha (mica) and uses thereof
|
WO2015003114A1
(en)
|
2013-07-05 |
2015-01-08 |
University Of Washington Through Its Center For Commercialization |
Soluble mic neutralizing monoclonal antibody for treating cancer
|
JP6380394B2
(ja)
|
2013-08-09 |
2018-08-29 |
アステラス製薬株式会社 |
新規抗ヒトtslp受容体抗体
|
US20160216262A1
(en)
|
2013-09-12 |
2016-07-28 |
Institut National De La Sante Et De La Recherche Medicale |
Method for In Vitro Quantifying Allo-Antibodies, Auto-Antibodies and/or Therapeutic Antibodies
|
AU2014322988B2
(en)
|
2013-09-20 |
2018-12-06 |
Westfaelische Wilhelms-Universitaet Muenster |
Cell-penetrating bacterial E3-ubiqitin-ligases for use in immunotherapy
|
CA2925087C
(en)
|
2013-09-24 |
2024-02-13 |
The Feinstein Institute For Medical Research |
Peptides inhibiting cold-inducible rna binding protein activity
|
ES2894333T3
(es)
|
2013-09-26 |
2022-02-14 |
Beth Israel Deaconess Medical Ct Inc |
Inhibidores de SGK1 en el tratamiento del síndrome de QT Largo
|
EP3061818B1
(de)
|
2013-09-30 |
2020-12-16 |
Daiichi Sankyo Company, Limited |
Anti-lps-o11-antikörper
|
EP3052131B1
(de)
|
2013-10-01 |
2018-12-05 |
Mayo Foundation for Medical Education and Research |
Verfahren zur krebsbehandlung bei patienten mit erhöhtem bim-spiegel
|
KR20160066024A
(ko)
|
2013-10-08 |
2016-06-09 |
다이이찌 산쿄 가부시키가이샤 |
항 fgfr2 항체와 타제의 조합
|
US20160264648A1
(en)
|
2013-11-06 |
2016-09-15 |
Osaka University |
Antibody having broad neutralization activity against group 1 influenza a viruses
|
HUE058272T2
(hu)
|
2013-11-06 |
2022-07-28 |
Janssen Biotech Inc |
Anti-CCL17 antitestek
|
EP3068419A1
(de)
|
2013-11-15 |
2016-09-21 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Verfahren und pharmazeutische zusammensetzungen zur behandlung von pankreaskarzinomen
|
WO2015082446A1
(en)
|
2013-12-02 |
2015-06-11 |
F. Hoffmann-La Roche Ag |
Treatment of cancer using an anti-cdcp1 antibody and a taxane
|
CN105829534B
(zh)
|
2013-12-24 |
2021-08-03 |
安斯泰来制药株式会社 |
抗人bdca-2抗体
|
PL3088419T3
(pl)
|
2013-12-25 |
2019-03-29 |
Daiichi Sankyo Company, Limited |
Koniugat lek-przeciwciało anty-trop2
|
WO2015104711A1
(en)
|
2014-01-09 |
2015-07-16 |
Hadasit Medical Research Services And Development Ltd. |
Improved cell compositions and methods for cancer therapy
|
WO2015106281A1
(en)
|
2014-01-13 |
2015-07-16 |
Baylor Research Institute |
Novel vaccines against hpv and hpv-related diseases
|
CN104774264B
(zh)
|
2014-01-15 |
2018-09-14 |
上海易乐生物技术有限公司 |
抗人proBDNF单克隆抗体及其在疼痛中的作用
|
CA2928794C
(en)
|
2014-01-31 |
2019-08-13 |
Daiichi Sankyo Company, Limited |
Anti-her2 antibody-drug conjugate
|
WO2015124570A1
(en)
|
2014-02-18 |
2015-08-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of influenza a virus infection
|
US20170051062A1
(en)
|
2014-02-18 |
2017-02-23 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and Pharmaceutical Compositions for the Treatment of Diseases Mediated by the NRP-1/OBR Complex Signaling Pathway
|
EP3415160B1
(de)
|
2014-03-04 |
2021-08-18 |
Klinikum der Universität München |
Aus enterococcus abgeleitete polypeptide und deren verwendung zur impfung und erstellung von therapeutischen antikörpern
|
WO2015140351A1
(en)
|
2014-03-21 |
2015-09-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for enhancing myelination
|
US20170174764A1
(en)
|
2014-03-27 |
2017-06-22 |
Yeda Research And Development Co. Ltd. |
T-cell receptor cdr3 peptides and antibodies
|
KR102186027B1
(ko)
|
2014-04-10 |
2020-12-03 |
다이이치 산쿄 유럽 게엠베하 |
항her3 항체-약물 콘주게이트
|
US11624093B2
(en)
|
2014-04-24 |
2023-04-11 |
Dana-Farber Cancer Institute, Inc. |
Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
|
CN106459204B
(zh)
|
2014-04-25 |
2021-02-02 |
皮埃尔法布雷医药公司 |
Igf-1r抗体及其作为定位载体用于治疗癌症的用途
|
AU2015250759B2
(en)
|
2014-04-25 |
2017-11-30 |
Pierre Fabre Medicament |
IGF-1R antibody-drug-conjugate and its use for the treatment of cancer
|
EP3607996B1
(de)
|
2014-04-25 |
2023-01-04 |
Pierre Fabre Medicament |
Antikörper-wirkstoff-konjugat und dessen verwendung bei der behandlung von krebs
|
KR102452349B1
(ko)
|
2014-04-27 |
2022-10-11 |
페임웨이브 리미티드 |
Ceacam1에 대한 인간화 항체
|
US11427647B2
(en)
|
2014-04-27 |
2022-08-30 |
Famewave Ltd. |
Polynucleotides encoding humanized antibodies against CEACAM1
|
WO2015179654A1
(en)
|
2014-05-22 |
2015-11-26 |
Mayo Foundation For Medical Education And Research |
Distinguishing antagonistic and agonistic anti b7-h1 antibodies
|
TWI713453B
(zh)
|
2014-06-23 |
2020-12-21 |
美商健生生物科技公司 |
干擾素α及ω抗體拮抗劑
|
US10273311B2
(en)
|
2014-06-26 |
2019-04-30 |
Yale University |
Compositions to regulate renalase in the treatment of diseases and disorders
|
WO2016011383A1
(en)
|
2014-07-17 |
2016-01-21 |
The Trustees Of The University Of Pennsylvania |
Methods for using exosomes to monitor transplanted organ status
|
CN105315375B
(zh)
|
2014-07-17 |
2021-04-23 |
恺兴生命科技(上海)有限公司 |
靶向cld18a2的t淋巴细胞及其制备方法和应用
|
EP3171896A4
(de)
|
2014-07-23 |
2018-03-21 |
Mayo Foundation for Medical Education and Research |
Abzielung auf dna-pkcs und b7-h1 zur behandlung von krebs
|
WO2016050822A2
(en)
|
2014-09-30 |
2016-04-07 |
Neurimmune Holding Ag |
Human-derived anti-dipeptide repeats (dprs) antibody
|
SG10201902924RA
(en)
|
2014-10-03 |
2019-05-30 |
Massachusetts Inst Technology |
Antibodies that bind ebola glycoprotein and uses thereof
|
US20170248603A1
(en)
|
2014-10-06 |
2017-08-31 |
Dana-Farber Cancer Institute, Inc. |
Angiopoiten-2 biomarkers predictive of anti-immune checkpoint response
|
WO2016057651A1
(en)
|
2014-10-09 |
2016-04-14 |
Dana-Farber Cancer Institute, Inc. |
Multiple-variable il-2 dose regimen for treating immune disorders
|
WO2016081835A2
(en)
|
2014-11-21 |
2016-05-26 |
University Of Maryland, Baltimore |
Targeted structure-specific particulate delivery systems
|
WO2016087889A1
(en)
|
2014-12-03 |
2016-06-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions using orexins (oxa, oxb) for the treatment of prostate cancers
|
WO2016128523A1
(en)
|
2015-02-12 |
2016-08-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease
|
AU2016229238B2
(en)
|
2015-03-06 |
2022-06-02 |
Dana-Farber Cancer Institute, Inc. |
PD-L2 biomarkers predictive of PD-1 pathway inhibitor responses in esophagogastric cancers
|
EP3067062A1
(de)
|
2015-03-13 |
2016-09-14 |
Ipsen Pharma S.A.S. |
Kombination von tasquinimod oder einem pharmazeutisch zulässigen salz davon und pd1 und/oder pdl1-hemmer zur verwendung als medikament
|
WO2016149621A1
(en)
|
2015-03-18 |
2016-09-22 |
The Johns Hopkins University |
Novel monoclonal antibody inhibitors targeting potassium channel kcnk9
|
US10426818B2
(en)
|
2015-03-24 |
2019-10-01 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Method and pharmaceutical composition for use in the treatment of diabetes
|
WO2016156557A1
(en)
|
2015-04-03 |
2016-10-06 |
Alienor Farma |
Monoclonal antibody to human line-1 orf2 protein and method for early detection of transforming cells in pre-neoplastic tissues of a human subject
|
US10851176B2
(en)
|
2015-04-13 |
2020-12-01 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods of administering neutralizing anti-protease nexin-1 antibodies to treat hemophilia A
|
EP3286221A1
(de)
|
2015-04-22 |
2018-02-28 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Verfahren und pharmazeutische zusammensetzungen zur behandlung von th17-vermittelten erkrankungen
|
EA201792661A1
(ru)
|
2015-06-01 |
2018-05-31 |
Медиджин Иммьюнотерапиз Гмбх |
Способ получения антител против т-клеточного рецептора
|
CN108026171A
(zh)
|
2015-06-01 |
2018-05-11 |
基因医疗免疫疗法有限责任公司 |
T细胞受体特异性抗体
|
WO2016193299A1
(en)
|
2015-06-01 |
2016-12-08 |
Medigene Immunotherapies Gmbh |
T cell receptor library
|
JP6948708B2
(ja)
|
2015-06-19 |
2021-10-13 |
センチュリオン バイオファーマ コーポレイション |
薬物制御放出のための送達系
|
WO2016210241A1
(en)
|
2015-06-26 |
2016-12-29 |
Beth Israel Deaconess Medical Center, Inc. |
Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells
|
WO2017002776A1
(ja)
|
2015-06-29 |
2017-01-05 |
第一三共株式会社 |
抗体-薬物コンジュゲートの選択的製造方法
|
EA201890434A1
(ru)
|
2015-08-05 |
2018-10-31 |
Янссен Байотек, Инк. |
Антитела к cd154 и способы их применения
|
US11078251B2
(en)
|
2015-09-18 |
2021-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
T cell receptors (TCR) and uses thereof for the diagnosis and treatment of diabetes
|
DK3353196T3
(da)
|
2015-09-22 |
2023-02-20 |
Inst Nat Sante Rech Med |
Polypeptider, der er i stand til at inhibere bindingen mellem leptin og neuropilin-1
|
MY194586A
(en)
|
2015-09-24 |
2022-12-05 |
Daiichi Sankyo Co Ltd |
Anti-garp antibody
|
WO2017059243A2
(en)
|
2015-09-30 |
2017-04-06 |
Janssen Biotech, Inc. |
Agonistic antibodies specifically binding human cd40 and methods of use
|
CN108138171B
(zh)
|
2015-10-08 |
2022-05-13 |
国立大学法人名古屋大学 |
表达嵌合抗原受体的基因修饰t细胞的制备方法
|
US11161912B2
(en)
|
2015-10-13 |
2021-11-02 |
Technion Research & Development Foundation Limited |
Heparanase-neutralizing monoclonal antibodies
|
WO2017064302A1
(en)
|
2015-10-16 |
2017-04-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases
|
RU2728568C2
(ru)
|
2015-10-26 |
2020-07-30 |
Пьер Фабр Медикамент |
Композиция для лечения рака, экспрессирующего igf-1r
|
WO2017075045A2
(en)
|
2015-10-30 |
2017-05-04 |
Mayo Foundation For Medical Education And Research |
Antibodies to b7-h1
|
ITUB20155272A1
(it)
|
2015-11-02 |
2017-05-02 |
Scuola Normale Superiore |
Intracellular antibody
|
AU2016348391A1
(en)
|
2015-11-03 |
2018-05-17 |
Janssen Biotech, Inc. |
Antibodies specifically binding TIM-3 and their uses
|
US20180320136A1
(en)
|
2015-11-03 |
2018-11-08 |
GlycoMimitics, Inc. |
Methods and compositions for the production of monoclonal antibodies, hematopoietic stem cells, and methods of using the same
|
ITUB20155097A1
(it)
|
2015-11-05 |
2017-05-05 |
Biouniversa Srl |
Anticorpi umanizzati anti-BAG3
|
WO2017097889A1
(en)
|
2015-12-10 |
2017-06-15 |
Katholieke Universiteit Leuven |
Anti adamts13 antibodies and their use for treatment or prevention of haemorrhagic disorders due to ventricular assist device
|
US20180355043A1
(en)
|
2015-12-17 |
2018-12-13 |
Janssen Biotech, Inc. |
Antibodies Specifically Binding HLA-DR and Their Uses
|
GB201522394D0
(en)
|
2015-12-18 |
2016-02-03 |
Ucb Biopharma Sprl |
Antibodies
|
MX2018007841A
(es)
|
2015-12-23 |
2018-11-09 |
Medigene Immunotherapies Gmbh |
Composicion de celula dendritica.
|
CN108780091A
(zh)
|
2015-12-31 |
2018-11-09 |
普莱戈斯瑞恩癌症有限责任公司 |
用于检测和治疗卵巢癌的组合物和方法
|
CN108700588A
(zh)
|
2015-12-31 |
2018-10-23 |
普莱戈斯瑞恩癌症有限责任公司 |
用于检测和治疗胃癌的组合物和方法
|
CA3193481A1
(en)
|
2015-12-31 |
2017-07-06 |
Progastrine Et Cancers S.A R.L. |
Compositions and methods for detecting and treating esophageal cancer
|
EP3202788A1
(de)
|
2016-02-05 |
2017-08-09 |
MediaPharma S.r.l. |
Endosialinbindender antikörper
|
JP7063813B2
(ja)
|
2016-02-15 |
2022-05-09 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
術後認知機能障害の処置のための方法及び医薬組成物
|
EP3205663A1
(de)
|
2016-02-15 |
2017-08-16 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Mittel und verfahren zur hemmung der genexpression
|
BR112018067522A2
(pt)
|
2016-03-01 |
2019-02-05 |
Univ Of Rijeka Faculty Of Medicine |
anticorpos específicos para receptor de poliovírus humano (pvr)
|
WO2017153432A1
(en)
|
2016-03-07 |
2017-09-14 |
Pierre Fabre Medicament |
A new universal method to capture and analyze adcs for characterization of drug distribution and the drug-to-antibody ratio in biological samples
|
WO2017156263A1
(en)
|
2016-03-09 |
2017-09-14 |
Memorial Sloan-Kettering Cancer Center |
Enigma and cdh18 as companion diagnostics for cdk4 inhibitors
|
US11740243B2
(en)
|
2016-03-15 |
2023-08-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Early and non invasive method for assessing a subject's risk of having pancreatic ductal adenocarcinoma and methods of treatment of such disease
|
WO2017158396A1
(en)
|
2016-03-16 |
2017-09-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cytidine deaminase inhibitors for the treatment of pancreatic cancer
|
US20190086392A1
(en)
|
2016-03-21 |
2019-03-21 |
Inserm (Institut National De La Sante Et De La Recherch Medicale) |
Methods for diagnosis and treatment of solar lentigo
|
EP3433277A4
(de)
|
2016-03-23 |
2020-06-17 |
Mabspace Biosciences (Suzhou) Co., Ltd |
Neuartige anti-pd-l1-antikörper
|
PT3436461T
(pt)
|
2016-03-28 |
2024-01-23 |
Incyte Corp |
Compostos de pirrolotriazina como inibidores de tam
|
ITUA20162242A1
(it)
|
2016-04-01 |
2017-10-01 |
St Biochimico Italiano Giovanni Lorenzini Spa |
Un nuovo anticorpo anti-erbb2
|
SI3445785T1
(sl)
|
2016-04-18 |
2022-11-30 |
Faron Pharmaceuticals Oy, |
Humanizirana protitelesa proti CLEVER-1 in njihova uporaba
|
EP3452512B1
(de)
|
2016-05-03 |
2023-03-08 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Verfahren und pharmazeutische zusammensetzungen zur behandlung von gewebeläsionen
|
ES2914118T3
(es)
|
2016-05-11 |
2022-06-07 |
Amgen Inc |
Selección directa de células que expresan niveles altos de proteínas heterodiméricas usando vectores de complementación intragénica de glutamina sintetasa
|
JP2019516799A
(ja)
|
2016-05-20 |
2019-06-20 |
カール、クリストフKARL, Christoph |
骨代謝の障害および低カルシウム血症などの治療誘発性副作用の処置および/または予防に適した、抗rankl抗体、カルシウムおよびビタミンdを含む薬学的組成物
|
WO2017202814A1
(en)
|
2016-05-24 |
2017-11-30 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of neuropathological disorders characterized by a loss of cortical neurons
|
EP3464357A1
(de)
|
2016-05-24 |
2019-04-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren und pharmazeutische zusammensetzungen zur behandlung von bakteriellen lungeninfektionen
|
EP3463396A1
(de)
|
2016-06-07 |
2019-04-10 |
Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft |
Chimärer antigenrezeptor und car-t-zellen zur bindung von bcma
|
GB201610198D0
(en)
|
2016-06-10 |
2016-07-27 |
Ucb Biopharma Sprl |
Anti-ige antibodies
|
HUE055402T2
(hu)
|
2016-07-06 |
2021-11-29 |
Prothena Biosciences Ltd |
Esszé összes és S129 foszforilezett alfa-szinuklein kimutatására
|
JP2018035137A
(ja)
|
2016-07-13 |
2018-03-08 |
マブイミューン ダイアグノスティックス エイジーMabimmune Diagnostics Ag |
新規な抗線維芽細胞活性化タンパク質(fap)結合薬剤およびその使用
|
MA45715A
(fr)
|
2016-07-25 |
2019-05-29 |
Biogen Ma Inc |
Anticorps anti-hspa5 (grp78) et leurs utilisations
|
WO2018019990A1
(en)
|
2016-07-28 |
2018-02-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of treatement of cancer disease by targetting tumor associated macrophage
|
CA3033665A1
(en)
|
2016-08-12 |
2018-02-15 |
Janssen Biotech, Inc. |
Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
|
CN109863170A
(zh)
|
2016-08-12 |
2019-06-07 |
詹森生物科技公司 |
具有增强的激动作用和效应子功能的工程化抗体及其他含Fc结构域分子
|
EP3515559A4
(de)
|
2016-09-20 |
2020-07-15 |
Dana-Farber Cancer Institute, Inc. |
Zusammensetzungen und verfahren zur identifizierung, beurteilung, prävention und behandlung von aml mit usp10-biomarkern und modulatoren
|
WO2018066626A1
(ja)
|
2016-10-07 |
2018-04-12 |
第一三共株式会社 |
抗her2抗体-薬物コンジュゲート投与による耐性癌の治療
|
WO2018070390A1
(ja)
|
2016-10-12 |
2018-04-19 |
第一三共株式会社 |
抗robo4抗体と他剤を含む組成物
|
CU20210030A7
(es)
|
2016-10-13 |
2021-11-04 |
Massachusetts Inst Technology |
Anticuerpos que se unen a la proteína de envoltura del virus zika
|
IT201600111877A1
(it)
|
2016-11-07 |
2018-05-07 |
Biouniversa Srl |
Anti-BAG3 antibodies in combination with inhibitors of immune check-point for therapeutic use
|
UA126388C2
(uk)
|
2016-11-18 |
2022-09-28 |
Астеллас Фарма Інк. |
Fab-фрагмент антитіла до muc1 людини
|
EP3552626A4
(de)
|
2016-12-12 |
2020-06-10 |
Daiichi Sankyo Company, Limited |
Kombination aus antikörper-wirkstoff-konjugat und immun-checkpoint-inhibitor
|
JP6996516B2
(ja)
|
2016-12-13 |
2022-01-17 |
アステラス製薬株式会社 |
抗ヒトcd73抗体
|
CA3047230A1
(en)
|
2016-12-15 |
2018-06-21 |
The National Institute for Biotechnology in the Negev Ltd. |
Anti-pcna monoclonal antibodies and use thereof
|
BR112019012901A2
(pt)
|
2016-12-22 |
2020-01-07 |
Daiichi Sankyo Company, Limited |
Anticorpo ou fragmento de ligação a antígeno do anticorpo, polinucleotídeo, vetor, célula, métodos para produzir um anticorpo ou um fragmento de ligação a antígeno do anticorpo e uma molécula que se ligue ao cd3 humano e ao cd3 de macaco cinomolgo, composição farmacêutica, e, molécula
|
US20180179490A1
(en)
|
2016-12-27 |
2018-06-28 |
Miltenyi Biotec Gmbh |
CELL COMPOSITION DEPLETED FROM TCRab and CD45RA POSITIVE CELLS
|
WO2018129284A1
(en)
|
2017-01-05 |
2018-07-12 |
The Johns Hopkins University |
Development of new monoclonal antibodies recognizing human prostate-specific membrane antigen (psma)
|
WO2018135501A1
(ja)
|
2017-01-17 |
2018-07-26 |
第一三共株式会社 |
抗gpr20抗体及び抗gpr20抗体-薬物コンジュゲート
|
WO2018140510A1
(en)
|
2017-01-25 |
2018-08-02 |
Biogen Ma Inc. |
Compositions and methods for treatment of stroke and other cns disorders
|
CA3052938A1
(en)
|
2017-02-07 |
2018-08-16 |
Daiichi Sankyo Company, Limited |
Anti-gprc5d antibody and molecule comprising the antibody
|
EP3363459A1
(de)
|
2017-02-17 |
2018-08-22 |
Alexander Klimka |
Polypeptid-epitope von s. aureus und entsprechende monoklonale antikörper zur behandlung von infektionen und immundiagnose
|
JP7325045B2
(ja)
|
2017-02-27 |
2023-08-14 |
カイロス セラピューティクス, インコーポレイテッド |
癌を処置する抗体コンストラクトおよび方法
|
WO2018159582A1
(ja)
|
2017-02-28 |
2018-09-07 |
学校法人近畿大学 |
抗her3抗体-薬物コンジュゲート投与によるegfr-tki抵抗性の非小細胞肺癌の治療方法
|
WO2018166495A1
(en)
|
2017-03-15 |
2018-09-20 |
Tsinghua University |
Novel anti-trkb antibodies
|
JOP20180021A1
(ar)
|
2017-03-16 |
2019-01-30 |
Janssen Biotech Inc |
الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها
|
US11879014B2
(en)
|
2017-03-17 |
2024-01-23 |
Tusk Therapeutics Ltd. |
Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
|
WO2018167283A1
(en)
|
2017-03-17 |
2018-09-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
|
TWI782000B
(zh)
|
2017-03-30 |
2022-11-01 |
日商第一三共股份有限公司 |
抗gpr20抗體、其製造方法及其應用
|
KR102351556B1
(ko)
|
2017-03-30 |
2022-01-14 |
프로가스트린 에 캔서스 에스.에이 알.엘. |
프로가스트린 결합 분자를 사용하는 전립선암의 검출 및 치료를 위한 조성물 및 방법
|
ES2925227T3
(es)
|
2017-03-30 |
2022-10-14 |
Ecs Progastrin Sa |
Composiciones y procedimientos para detectar el cáncer de pulmón
|
US10722589B2
(en)
|
2017-04-03 |
2020-07-28 |
Covagen Ag |
FGFR3 binding molecules
|
WO2018185516A1
(en)
|
2017-04-05 |
2018-10-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy
|
WO2018189335A1
(en)
|
2017-04-13 |
2018-10-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
|
WO2018189403A1
(en)
|
2017-04-14 |
2018-10-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of cancer
|
US20190016810A1
(en)
|
2017-05-11 |
2019-01-17 |
Cytodyn Inc. |
Methods for treating or preventing graft-versus-host disease involving the administration of anti-ccr5 receptor agents
|
TW202330036A
(zh)
|
2017-05-15 |
2023-08-01 |
日商第一三共股份有限公司 |
抗體-藥物結合物之製造方法
|
AU2018282094A1
(en)
|
2017-06-05 |
2019-12-12 |
Janssen Biotech, Inc. |
Antibodies that specifically bind PD-1 and methods of use
|
EP3634496A4
(de)
|
2017-06-06 |
2021-09-08 |
Dana-Farber Cancer Institute, Inc. |
Verfahren zur sensibilisierung von krebszellen gegen t-zell-vermittelte abtötung mittels modulierung von molekularen signalwegen
|
US20210145828A1
(en)
|
2017-06-29 |
2021-05-20 |
Rutgers, The State University Of New Jersey |
Compositions And Methods Targeting G12 Signaling For Bronchodilator Therapy
|
JP7181535B2
(ja)
|
2017-06-30 |
2022-12-01 |
国立大学法人北海道大学 |
成長障害を生じない小児骨粗鬆症治療薬
|
TWI795415B
(zh)
|
2017-07-07 |
2023-03-11 |
日商安斯泰來製藥股份有限公司 |
新穎的抗人類CEACAM5抗體Fab片段
|
EP3655031A1
(de)
|
2017-07-21 |
2020-05-27 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Immunogene zusammensetzungen gegen neisseria meningitidis
|
KR20200032185A
(ko)
|
2017-07-27 |
2020-03-25 |
다이이찌 산쿄 가부시키가이샤 |
항 cd147 항체
|
US20210024623A1
(en)
|
2017-07-28 |
2021-01-28 |
Intrepida Bio, Inc. |
Anti-bag3 antibodies as therapeutic reagent in cardiovascular disease
|
CN117050176A
(zh)
|
2017-07-31 |
2023-11-14 |
豪夫迈·罗氏有限公司 |
基于三维结构的人源化方法
|
EP3444272A1
(de)
|
2017-08-17 |
2019-02-20 |
International-Drug-Development-Biotech |
Behandlung von ck8-positivem krebs in verbindung mit dem k-ras-genstatus
|
WO2019038368A1
(en)
|
2017-08-23 |
2019-02-28 |
Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft |
CHIMERIC ANTIGEN RECEPTOR AND CAR CXCR5 BINDING T CARRIER
|
JP7204651B2
(ja)
|
2017-08-23 |
2023-01-16 |
第一三共株式会社 |
抗体-薬物コンジュゲートの製剤及びその凍結乾燥方法
|
US11318212B2
(en)
|
2017-08-31 |
2022-05-03 |
Daiichi Sankyo Company, Limited |
Method for producing antibody-drug conjugate
|
AU2018327171B2
(en)
|
2017-08-31 |
2023-03-09 |
Daiichi Sankyo Company, Limited |
Improved method for producing antibody-drug conjugate
|
US10610585B2
(en)
|
2017-09-26 |
2020-04-07 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and compositions for treating and preventing HIV
|
BR112020004126A2
(pt)
|
2017-09-29 |
2020-09-08 |
Daiichi Sankyo Company, Limited |
conjugado anticorpo-derivado de pirrolbenzodiazepina
|
WO2019069561A1
(ja)
|
2017-10-03 |
2019-04-11 |
公益財団法人東京都医学総合研究所 |
インフルエンザに対する医薬
|
TW201927336A
(zh)
|
2017-10-05 |
2019-07-16 |
日商第一三共股份有限公司 |
細胞毒性t細胞耗竭用組成物
|
KR101966362B1
(ko)
*
|
2017-10-20 |
2019-04-05 |
주식회사 녹십자 |
항-msln 항체 및 이를 포함하는 암 치료용 약학적 조성물
|
EP3706795A4
(de)
|
2017-11-09 |
2021-10-13 |
Pinteon Therapeutics Inc. |
Verfahren und zusammensetzungen zur erzeugung und verwendung von humanisierten konformationsspezifischen phosphorylierten tau-antikörpern
|
JP7442821B2
(ja)
|
2017-11-30 |
2024-03-05 |
センチュリオン バイオファーマ コーポレイション |
メイタンシノイド系薬物送達システム
|
DK3717503T3
(da)
|
2017-11-30 |
2024-01-22 |
Ladrx Corp |
Albumin-bindende prodrugs af auristatin E derivater
|
WO2019106126A1
(en)
|
2017-12-01 |
2019-06-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Mdm2 modulators for the diagnosis and treatment of liposarcoma
|
KR102461238B1
(ko)
|
2017-12-05 |
2022-11-01 |
프로가스트린 에 캔서스 에스.에이 알.엘. |
암을 치료하기 위한 항-프로가스트린 항체와 면역치료 사이의 병용 치료
|
WO2019121872A1
(en)
|
2017-12-20 |
2019-06-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the diagnosis and treatment of liver cancer
|
US20190225689A1
(en)
|
2018-01-22 |
2019-07-25 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-pd-1 antibodies
|
TW201940881A
(zh)
|
2018-01-26 |
2019-10-16 |
瑞士商Ecs前胃泌激素公司 |
在癌症診斷中結合前胃泌激素檢測與其他癌症生物標記的技術
|
EP3752252A4
(de)
|
2018-02-12 |
2021-11-17 |
Hadasit Medical Research Services and Development Ltd. |
Modulation von slamf6-spleissvarianten für die krebstherapie
|
WO2019158512A1
(en)
|
2018-02-13 |
2019-08-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the prognosis and the treatment of glioblastoma
|
AU2019227607C1
(en)
|
2018-02-27 |
2023-07-20 |
Incyte Corporation |
Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
|
EP3759492A1
(de)
|
2018-02-27 |
2021-01-06 |
ECS-Progastrin SA |
Progastrin als biomarker für immuntherapie
|
JP7125979B2
(ja)
|
2018-03-05 |
2022-08-25 |
学校法人 埼玉医科大学 |
異所性骨化の治療又は予防のための医薬組成物
|
US20210047696A1
(en)
|
2018-03-28 |
2021-02-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cancer
|
US20210164984A1
(en)
|
2018-04-13 |
2021-06-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting outcome and treatment of patients suffering from prostate cancer or breast cancer
|
WO2019201995A1
(en)
|
2018-04-20 |
2019-10-24 |
Medizinische Hochschule Hannover |
Chimeric antigen receptor and car-t cells that bind a herpes virus antigen
|
WO2019207066A1
(en)
|
2018-04-26 |
2019-10-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for the treatment of sjögren's syndrome
|
WO2019211370A1
(en)
|
2018-05-03 |
2019-11-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cancer
|
WO2019211369A1
(en)
|
2018-05-03 |
2019-11-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cancer
|
CA3097679A1
(en)
|
2018-05-09 |
2019-11-14 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Antibodies specific to human nectin4
|
US20210163549A1
(en)
|
2018-05-11 |
2021-06-03 |
Astellas Pharma Inc. |
Nucleic acid for treating crustacean allergy
|
AR115379A1
(es)
|
2018-05-11 |
2021-01-13 |
Astellas Pharma Inc |
Ácido nucleico para tratar alergia a los ácaros
|
WO2019221269A1
(ja)
|
2018-05-17 |
2019-11-21 |
アステラス製薬株式会社 |
抗ヒトMUC1抗体Fabフラグメント、ペプチドリンカー及び/又は配位子を含む複合体
|
JP7391046B2
(ja)
|
2018-05-18 |
2023-12-04 |
インサイト・コーポレイション |
A2a/a2b阻害剤としての縮合ピリミジン誘導体
|
EP3802607A2
(de)
|
2018-05-24 |
2021-04-14 |
Janssen Biotech, Inc. |
Monospezifische und multispezifische anti-tmeff2-antikörper und ihre verwendung
|
BR112020023508A2
(pt)
|
2018-05-24 |
2021-03-30 |
Janssen Biotech, Inc. |
Anticorpos anti-cd3 e usos dos mesmos
|
EP3802609A2
(de)
|
2018-05-24 |
2021-04-14 |
Janssen Biotech, Inc. |
Psma-bindende stoffe und verwendungen davon
|
BR112020024061A2
(pt)
|
2018-05-28 |
2021-02-17 |
Daiichi Sankyo Company, Limited |
agente terapêutico para câncer com her2 mutado
|
AR126019A1
(es)
|
2018-05-30 |
2023-09-06 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
CN112204143B
(zh)
|
2018-05-31 |
2024-03-08 |
第一三共株式会社 |
抗人tlr7抗体
|
BR112020024351A2
(pt)
|
2018-06-01 |
2021-02-23 |
Novartis Ag |
moléculas de ligação contra bcma e usos das mesmas
|
WO2019234099A1
(en)
|
2018-06-06 |
2019-12-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosing, predicting the outcome and treating a patient suffering from heart failure with preserved ejection fraction
|
WO2019234221A1
(en)
|
2018-06-08 |
2019-12-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia
|
EP3810651A1
(de)
|
2018-06-20 |
2021-04-28 |
Incyte Corporation |
Anti-pd-1-antikörper und verwendungen davon
|
TW202016144A
(zh)
|
2018-06-21 |
2020-05-01 |
日商第一三共股份有限公司 |
包括cd3抗原結合片段之組成物及其用途
|
TWI832871B
(zh)
|
2018-06-29 |
2024-02-21 |
美商英塞特公司 |
Axl/mer 抑制劑之調配物
|
WO2020007898A1
(en)
|
2018-07-04 |
2020-01-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating brain injury or neurodegenerative disease
|
TW202019972A
(zh)
|
2018-07-25 |
2020-06-01 |
日商第一三共股份有限公司 |
抗體-藥物結合物之有效的製造方法
|
EP3831853A4
(de)
|
2018-07-27 |
2022-06-01 |
Daiichi Sankyo Company, Limited |
Protein-erkennende arzneimitteleinheit eines antikörper-wirkstoff-konjugats
|
JP7182308B2
(ja)
|
2018-07-27 |
2022-12-02 |
国立大学法人大阪大学 |
老化の抑制、加齢性の疾患もしくは症状の予防、改善、もしくは治療、または寿命の延長のための組成物
|
KR20210038625A
(ko)
|
2018-07-31 |
2021-04-07 |
다이이찌 산쿄 가부시키가이샤 |
항체-약물 콘주게이트 투여에 의한 전이성 뇌종양의 치료
|
CN112512587A
(zh)
|
2018-08-06 |
2021-03-16 |
第一三共株式会社 |
抗体药物缀合物和微管蛋白抑制剂的组合
|
CN112714649A
(zh)
|
2018-09-06 |
2021-04-27 |
第一三共株式会社 |
新型环状二核苷酸衍生物及其抗体药物偶联物
|
CN112912109A
(zh)
|
2018-09-20 |
2021-06-04 |
第一三共株式会社 |
通过施用抗her3抗体-药物缀合物治疗her3-突变的癌症
|
JP7475687B2
(ja)
|
2018-09-21 |
2024-04-30 |
国立大学法人 東京医科歯科大学 |
ヒトhmgb1に特異的に結合するヒトモノクローナル抗体、及びそれを含有するアルツハイマー病を治療又は予防するための医薬組成物
|
KR20210065991A
(ko)
|
2018-09-27 |
2021-06-04 |
피에르 파브르 메디카먼트 |
설포말레이미드계 링커 및 상응하는 컨쥬게이트
|
US20220048966A1
(en)
|
2018-09-28 |
2022-02-17 |
Pierre Fabre Medicament |
New immunocytokines for the treatment of cancer
|
EP3865154A4
(de)
|
2018-10-10 |
2022-11-09 |
Astellas Pharma Inc. |
Pharmazeutische zusammensetzung mit einem anti-humanen site-markierten antikörper-fab-fragment-komplex
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
WO2020079164A1
(en)
|
2018-10-18 |
2020-04-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combination of a big-h3 antagonist and an immune checkpoint inhibitor for the treatment of solid tumor
|
EP3875114A4
(de)
|
2018-10-31 |
2022-08-10 |
Astellas Pharma Inc. |
Antikörper gegen menschliches fn14
|
WO2020099235A1
(en)
|
2018-11-12 |
2020-05-22 |
Mediapharma S.R.L. |
Bispecific antibodies directed against human 90k and either endosialin or her3
|
AU2019379418A1
(en)
|
2018-11-14 |
2021-06-03 |
Daiichi Sankyo Company, Limited |
Anti-CDH6 antibody-pyrrolobenzodiazepine derivative conjugate
|
TW202034959A
(zh)
|
2018-12-11 |
2020-10-01 |
日商第一三共股份有限公司 |
抗體-藥物結合物與parp抑制劑之組合
|
US20220040324A1
(en)
|
2018-12-21 |
2022-02-10 |
Daiichi Sankyo Company, Limited |
Combination of antibody-drug conjugate and kinase inhibitor
|
NL2024544B1
(en)
|
2018-12-21 |
2021-03-15 |
Aim Immunotech Inc |
Compositions And Methods For Cancer Therapy
|
MX2021008230A
(es)
|
2019-01-07 |
2021-08-11 |
Astellas Pharma Inc |
Conjugado que comprende ligando y fragmento fab de anticuerpo ceacam5.
|
TW202043256A
(zh)
|
2019-01-10 |
2020-12-01 |
美商健生生物科技公司 |
前列腺新抗原及其用途
|
AU2020207664A1
(en)
|
2019-01-13 |
2021-07-22 |
University Of Rijeka Faculty Of Medicine |
Antibodies specific to human Nectin-2
|
TWI829857B
(zh)
|
2019-01-29 |
2024-01-21 |
美商英塞特公司 |
作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
|
EP3917515A1
(de)
|
2019-01-29 |
2021-12-08 |
Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
Behandlung des verursachenden mittels in der adhäsiogenese
|
JP2022520088A
(ja)
|
2019-02-13 |
2022-03-28 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド |
抗末梢リンパ節アドレッシン抗体およびその使用
|
WO2020178193A1
(en)
|
2019-03-01 |
2020-09-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method of treatment of sarcoidosis
|
WO2020193441A1
(en)
|
2019-03-22 |
2020-10-01 |
Université de Paris |
New inhibitors of lrrk2/pp1 interaction
|
JPWO2020196474A1
(de)
|
2019-03-25 |
2020-10-01 |
|
|
KR20210141630A
(ko)
|
2019-03-25 |
2021-11-23 |
다이이찌 산쿄 가부시키가이샤 |
항 her2 항체-피롤로벤조디아제핀 유도체 콘주게이트
|
WO2020193628A1
(en)
|
2019-03-25 |
2020-10-01 |
Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft |
Enhancement of cytolytic t-cell activity by inhibiting ebag9
|
JPWO2020196712A1
(de)
|
2019-03-27 |
2020-10-01 |
|
|
CN113660954A
(zh)
|
2019-04-01 |
2021-11-16 |
凯奥目生物科学株式会社 |
癌症治疗用药物
|
JP2022527860A
(ja)
|
2019-04-02 |
2022-06-06 |
ケンジョッケティ バイオテクノロジー,インク. |
排出ポンプ-癌抗原マルチ特異性抗体ならびにそれに関する組成物、試薬、キットおよび方法
|
KR20220002899A
(ko)
|
2019-04-19 |
2022-01-07 |
얀센 바이오테크 인코포레이티드 |
항-psma/cd3 항체로 전립선암을 치료하는 방법
|
EP3962529A4
(de)
|
2019-04-30 |
2023-11-01 |
Dana-Farber Cancer Institute, Inc. |
Verfahren zur krebsbehandlung unter verwendung von kombinationen aus anti-cx3cr1 und immuncheckpoint-blockierungsreagenzien
|
US20220259561A1
(en)
|
2019-05-14 |
2022-08-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Regulatory t cells targeted by lymphotoxin alpha blocking agent and uses thereof
|
CA3142119A1
(en)
|
2019-05-29 |
2020-12-03 |
Daiichi Sankyo Company, Limited |
Dosage of an antibody-drug conjugate for treating cancer
|
US20220332821A1
(en)
|
2019-06-24 |
2022-10-20 |
Novartis Ag |
Dosing regimen and combination therapies for multispecific antibodies targeting b-cell maturation antigen
|
TW202118788A
(zh)
|
2019-07-26 |
2021-05-16 |
美商健生生物科技公司 |
包含血管舒緩素相關肽酶2抗原結合域之蛋白質及其用途
|
EP4008350A4
(de)
|
2019-07-26 |
2023-06-14 |
Saitama Medical University |
Antikörper, der die extrazelluläre region von alk2/acvr1 erkennt
|
WO2021019706A1
(ja)
|
2019-07-31 |
2021-02-04 |
国立大学法人信州大学 |
Car発現免疫細胞を含む細胞集団の製造方法
|
JP2022543062A
(ja)
|
2019-08-01 |
2022-10-07 |
インサイト・コーポレイション |
Ido阻害剤の投与レジメン
|
CN114502594A
(zh)
|
2019-08-02 |
2022-05-13 |
西托戴恩股份有限公司 |
牵涉施用抗-ccr5受体试剂的用于治疗或预防癌症的方法
|
CA3150428A1
(en)
|
2019-08-12 |
2021-02-18 |
Biond Biologics Ltd. |
Antibodies against ilt2 and use thereof
|
EP3792632A1
(de)
|
2019-09-16 |
2021-03-17 |
Vito NV |
Immuntherapiemarker
|
EP4031578A1
(de)
|
2019-09-18 |
2022-07-27 |
Novartis AG |
Entpd2-antikörper, kombinationstherapien und verfahren zur verwendung der antikörper und kombinationstherapien
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與entpd2抗體之組合療法
|
WO2021058744A1
(en)
|
2019-09-27 |
2021-04-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of müllerian inhibiting substance inhibitors for treating cancer
|
EP4034160A1
(de)
|
2019-09-27 |
2022-08-03 |
Janssen Biotech, Inc. |
Anti-ceacam-antikörper und verwendungen davon
|
EP4049675A4
(de)
|
2019-10-25 |
2023-11-22 |
Daiichi Sankyo Company, Limited |
Kombination von anti-garp-antikörper und immunregulator
|
US20210147526A1
(en)
|
2019-11-15 |
2021-05-20 |
Pliant Therapeutics, Inc. |
Compositions and methods for activation of integrins
|
IL293051A
(en)
|
2019-11-18 |
2022-07-01 |
Janssen Biotech Inc |
calr and jak2 mutant-based vaccines and their uses
|
BR112022011226A2
(pt)
*
|
2019-12-10 |
2022-08-30 |
Ccoa Therapeutics Inc |
Anticorpos antiglicoproteína ib alfa (gpibalpha) humanizados
|
US11396541B2
(en)
|
2019-12-20 |
2022-07-26 |
Novarock Biotherapeutics, Ltd. |
Anti-interleukin-23 P19 antibodies and methods of use thereof
|
WO2021138512A1
(en)
|
2020-01-03 |
2021-07-08 |
Incyte Corporation |
Combination therapy comprising a2a/a2b and pd-1/pd-l1 inhibitors
|
WO2021140173A1
(en)
|
2020-01-10 |
2021-07-15 |
Biouniversa S.R.L. |
Methods and uses for treating fibrotic solid tumors with bags inhibitors
|
EP4100525A1
(de)
|
2020-02-05 |
2022-12-14 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Verfahren zur behandlung von krebserkrankungen durch targeting eines epigenetischen faktors
|
TW202140012A
(zh)
|
2020-02-12 |
2021-11-01 |
比利時商健生藥品公司 |
用於治療尿路上皮癌的fgfr酪胺酸激酶抑制劑和抗pd1藥劑
|
TW202144389A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在多發性骨髓瘤中表現之新抗原及其用途
|
TW202144388A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在卵巢癌中表現之新抗原及其用途
|
EP4114368A1
(de)
|
2020-03-03 |
2023-01-11 |
Active Biotech AB |
Tasquinimod oder pharmazeutisch unbedenkliches salz davon zur verwendung in der kombinationstherapie
|
KR20220151630A
(ko)
|
2020-03-06 |
2022-11-15 |
다이이찌 산쿄 가부시키가이샤 |
신규 고리형 디뉴클레오티드 유도체를 포함하는 항체 약물 컨쥬게이트
|
CA3174539A1
(en)
|
2020-03-06 |
2021-09-10 |
Incyte Corporation |
Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
|
CA3173981A1
(en)
|
2020-03-10 |
2021-09-16 |
Massachusetts Institute Of Technology |
Compositions and methods for immunotherapy of npm1c-positive cancer
|
KR20220154728A
(ko)
|
2020-03-13 |
2022-11-22 |
얀센 바이오테크 인코포레이티드 |
Siglec-3/cd33을 결합시키기 위한 물질 및 방법
|
US11045546B1
(en)
|
2020-03-30 |
2021-06-29 |
Cytodyn Inc. |
Methods of treating coronavirus infection
|
JPWO2021200131A1
(de)
|
2020-03-30 |
2021-10-07 |
|
|
EP3889183A1
(de)
|
2020-04-01 |
2021-10-06 |
Pierre Fabre Medicament |
Proteinkomplex mit einem immunzytokin
|
AU2021253899A1
(en)
|
2020-04-06 |
2022-11-17 |
University Of Rijeka Faculty Of Medicine |
Antibodies to NKp46 and constructs thereof for treatment of cancers and infections
|
WO2021228218A1
(zh)
|
2020-05-14 |
2021-11-18 |
江苏恒瑞医药股份有限公司 |
抗cd25抗体、其抗原结合片段及其医药用途
|
WO2021233962A1
(en)
|
2020-05-19 |
2021-11-25 |
Institut Curie |
Methods for the diagnosis and treatment of cytokine release syndrome
|
BR112022023931A2
(pt)
|
2020-05-27 |
2023-04-11 |
Arialys Therapeutics Inc |
Derivado de anticorpo nr1 anti-humano
|
KR20230017841A
(ko)
|
2020-05-27 |
2023-02-06 |
얀센 바이오테크 인코포레이티드 |
Cd3 항원 결합 도메인을 포함하는 단백질 및 이의 용도
|
WO2021247423A1
(en)
|
2020-06-04 |
2021-12-09 |
Kenjockety Biotechnology, Inc. |
Abcg2 efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto
|
JP2023542065A
(ja)
|
2020-06-24 |
2023-10-05 |
アストラゼネカ ユーケー リミテッド |
抗体-薬物複合物及びcdk9阻害剤の組み合わせ
|
KR20230043109A
(ko)
|
2020-06-24 |
2023-03-30 |
아스트라제네카 유케이 리미티드 |
항체-약물 접합체 및 atr 억제제의 조합
|
WO2021260582A1
(en)
|
2020-06-24 |
2021-12-30 |
Astrazeneca Uk Limited |
Combination of antibody-drug conjugate and aurora b inhibitor
|
EP4171651A1
(de)
|
2020-06-24 |
2023-05-03 |
AstraZeneca UK Limited |
Kombination aus antikörper-wirkstoff-konjugat und atm-inhibitor
|
WO2021260583A1
(en)
|
2020-06-24 |
2021-12-30 |
Astrazeneca Uk Limited |
Combination of antibody-drug conjugate and dna-pk inhibitor
|
EP4171527A1
(de)
|
2020-06-25 |
2023-05-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren zur behandlung und diagnose pathologischer zustände in zusammenhang mit intensivem stress
|
TW202216212A
(zh)
|
2020-07-17 |
2022-05-01 |
日商第一三共股份有限公司 |
抗體-藥物結合物之製造方法
|
US20230293714A1
(en)
|
2020-07-20 |
2023-09-21 |
Daiichi Sankyo Company, Limited |
Combination of anti-her2 antibody-drug conjugate with her dimerization inhibitor
|
AR123083A1
(es)
|
2020-07-29 |
2022-10-26 |
Janssen Biotech Inc |
Proteínas que comprenden dominios de unión al antígeno hla-g y sus usos
|
RU2764216C1
(ru)
*
|
2020-08-10 |
2022-01-14 |
Федеральное государственное бюджетное образовательное учреждение высшего образования "Чувашский государственный университет имени И.Н. Ульянова" |
Способ лечения гломерулонефритов с нефротическим синдромом рецидивирующего течения
|
MX2023001776A
(es)
|
2020-08-12 |
2023-03-10 |
Biond Biologics Ltd |
Anticuerpos contra ilt2 y uso de los mismos.
|
JP2023540023A
(ja)
|
2020-08-24 |
2023-09-21 |
シャリテ-ウニベルジテーツメディツィン ベルリン |
Ceaを認識するキメラ抗原受容体(car)発現細胞
|
JP2023540022A
(ja)
|
2020-08-24 |
2023-09-21 |
シャリテ-ウニベルジテーツメディツィン ベルリン |
チェックポイント阻害分子及び免疫刺激性サイトカインをコードするキメラ抗原受容体構築物、並びにCD44v6を認識するCAR発現細胞
|
AU2021337687A1
(en)
|
2020-09-04 |
2023-03-23 |
Novarock Biotherapeutics, Ltd. |
Nectin-4 antibodies and uses thereof
|
WO2022049273A1
(en)
|
2020-09-07 |
2022-03-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of treatment of inflammatory bowel diseases
|
AU2021340002A1
(en)
|
2020-09-12 |
2023-05-25 |
Astrazeneca Uk Limited |
A scoring method for an anti-her2 antibody-drug conjugate therapy
|
EP4226945A1
(de)
|
2020-10-05 |
2023-08-16 |
Chiome Bioscience, Inc |
Arzneimittel zur behandlung von krebs
|
KR20230084163A
(ko)
|
2020-10-09 |
2023-06-12 |
아스트라제네카 유케이 리미티드 |
항체-약물 접합체와 parp1 선택적 억제제의 조합
|
JP2023544890A
(ja)
|
2020-10-13 |
2023-10-25 |
ヤンセン バイオテツク,インコーポレーテツド |
分化抗原群iv及び/又はviiiを調節するための生物工学的に作製されたt細胞媒介免疫、材料及び他の方法
|
WO2022084399A1
(en)
|
2020-10-21 |
2022-04-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
C-terminal sparc fragments for treating cancer
|
EP4232479A1
(de)
|
2020-10-22 |
2023-08-30 |
Janssen Biotech, Inc. |
Proteine mit delta-like ligand-3 (dll3)-antigenbindenden domänen und deren verwendungen
|
WO2022097090A1
(en)
|
2020-11-05 |
2022-05-12 |
Novartis Ag |
Dosing regimen for combination therapies with multispecific antibodies targeting b-cell maturation antigen and gamma secretase inhibitors
|
WO2022096633A1
(en)
|
2020-11-06 |
2022-05-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosis and treating polycystic ovary syndrome (pcos)
|
JPWO2022102634A1
(de)
|
2020-11-11 |
2022-05-19 |
|
|
US20230398230A1
(en)
|
2020-11-12 |
2023-12-14 |
Daiichi Sankyo Company, Limited |
Treatment of mesothelioma by administration of anti-b7-h3 antibody-drug conjugate
|
WO2022102768A1
(ja)
|
2020-11-16 |
2022-05-19 |
アステラス製薬株式会社 |
抗tspan8-抗cd3二重特異性抗体及び抗tspan8抗体
|
US20240003879A1
(en)
|
2020-11-27 |
2024-01-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosis and monitoring of toxic epidermal necrolysis
|
JP2023551519A
(ja)
|
2020-11-30 |
2023-12-08 |
インサイト・コーポレイション |
抗cd19抗体とパルサクリシブの組み合わせ療法
|
WO2022115120A1
(en)
|
2020-11-30 |
2022-06-02 |
Incyte Corporation |
Combination therapy with an anti-cd19 antibody and parsaclisib
|
JPWO2022124247A1
(de)
|
2020-12-09 |
2022-06-16 |
|
|
US20220233529A1
(en)
|
2020-12-29 |
2022-07-28 |
Incyte Corporation |
Combination therapy comprising a2a/a2b inhibitors, pd-1/pd-l1 inhibitors, and anti-cd73 antibodies
|
WO2022153195A1
(en)
|
2021-01-13 |
2022-07-21 |
Memorial Sloan Kettering Cancer Center |
Anti-dll3 antibody-drug conjugate
|
WO2022153212A1
(en)
|
2021-01-13 |
2022-07-21 |
Axon Neuroscience Se |
Antibodies neutralizing sars-cov-2
|
TW202237135A
(zh)
|
2021-01-13 |
2022-10-01 |
紀念斯隆凱特琳癌症中心 |
抗體-吡咯并苯并二氮呯衍生物結合物
|
WO2022162518A2
(en)
|
2021-01-28 |
2022-08-04 |
Janssen Biotech, Inc. |
Psma binding proteins and uses thereof
|
JP2024505049A
(ja)
|
2021-01-29 |
2024-02-02 |
ノバルティス アーゲー |
抗cd73及び抗entpd2抗体のための投与方式並びにその使用
|
TW202241454A
(zh)
|
2021-02-01 |
2022-11-01 |
日商第一三共股份有限公司 |
抗體-免疫賦活化劑共軛物之新穎製造方法
|
MX2023009434A
(es)
|
2021-02-11 |
2023-08-15 |
Nectin Therapeutics Ltd |
Anticuerpos contra cd112r y usos de los mismos.
|
AU2022219517A1
(en)
|
2021-02-12 |
2023-07-13 |
Boehringer Ingelheim International Gmbh |
Complement c3 antigen binding proteins
|
US20220378929A1
(en)
|
2021-02-25 |
2022-12-01 |
MediBoston Limted |
Anti-her2 antibody-drug conjugates and uses thereof
|
KR20230165212A
(ko)
|
2021-03-02 |
2023-12-05 |
다나-파버 캔서 인스티튜트 인크. |
적혈구 장애의 치료 방법
|
WO2022189632A1
(en)
|
2021-03-12 |
2022-09-15 |
Fibrosys S.R.L. |
Monoclonal antibodies for the treatment of viral infections
|
CA3212691A1
(en)
|
2021-03-12 |
2022-09-15 |
Daiichi Sankyo Company, Limited |
Glycan, and method for producing medicine containing glycan
|
IL306103A
(en)
|
2021-03-24 |
2023-11-01 |
Janssen Biotech Inc |
The antibody targets CD22 and CD79B
|
US20240166731A1
(en)
|
2021-03-26 |
2024-05-23 |
Janssen Biotech, Inc. |
Humanized antibodies against paired helical filament tau and uses thereof
|
WO2022218998A1
(en)
|
2021-04-13 |
2022-10-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for treating hepatitis b and d virus infection
|
AU2022256455A1
(en)
|
2021-04-14 |
2023-10-12 |
Villaris Therapeutics, Inc. |
Anti-cd122 antibodies and uses thereof
|
AR125398A1
(es)
|
2021-04-22 |
2023-07-12 |
Astellas Pharma Inc |
Anticuerpo biespecífico anti-cldn4 / anti-cd137
|
WO2022261183A2
(en)
|
2021-06-08 |
2022-12-15 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
|
CN113361141B
(zh)
*
|
2021-07-11 |
2022-02-18 |
西南石油大学 |
一种dna图谱算法的改进试验方法
|
IL311070A
(en)
|
2021-08-27 |
2024-04-01 |
Janssen Biotech Inc |
Anti-PSMA antibodies and uses thereof
|
CA3231632A1
(en)
|
2021-09-15 |
2023-03-23 |
Daiichi Sankyo Company, Limited |
Antibody-drug conjugate for use in methods of treating chemotherapy-resistant cancer
|
WO2023041744A1
(en)
|
2021-09-17 |
2023-03-23 |
Institut Curie |
Bet inhibitors for treating pab1 deficient cancer
|
WO2023046322A1
(en)
|
2021-09-24 |
2023-03-30 |
Janssen Pharmaceutica Nv |
Proteins comprising cd20 binding domains, and uses thereof
|
WO2023052541A1
(en)
|
2021-09-30 |
2023-04-06 |
Imcheck Therapeutics |
Combination of an anti-btn3a activating antibody and an il-2 agonist for use in therapy
|
WO2023068226A1
(ja)
|
2021-10-18 |
2023-04-27 |
第一三共株式会社 |
抗cd37抗体-薬物コンジュゲート
|
AU2022378932A1
(en)
|
2021-10-27 |
2024-05-02 |
Assistance Publique Hopitaux De Marseille |
Butyrophilin (btn) 3a activating antibodies for use in methods for treating infectious disorders
|
EP4177266A1
(de)
|
2021-11-05 |
2023-05-10 |
Katholieke Universiteit Leuven |
Neutralisierende humane anti-sars-cov-2-antikörper
|
TW202329936A
(zh)
|
2021-11-18 |
2023-08-01 |
英商阿斯特捷利康英國股份有限公司 |
抗體-藥物結合物與parp1選擇性抑制劑之組合
|
WO2023089032A1
(en)
|
2021-11-19 |
2023-05-25 |
Institut Curie |
Methods for the treatment of hrd cancer and brca-associated cancer
|
WO2023097119A2
(en)
|
2021-11-29 |
2023-06-01 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions to modulate riok2
|
WO2023099763A1
(en)
|
2021-12-03 |
2023-06-08 |
Institut Curie |
Sirt6 inhibitors for use in treating resistant hrd cancer
|
WO2023105528A1
(en)
|
2021-12-12 |
2023-06-15 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Antibodies specific to ceacam1
|
TW202334231A
(zh)
|
2021-12-22 |
2023-09-01 |
德商莫菲西斯公司 |
抗cd19抗體療法的治療範例
|
WO2023126822A1
(en)
|
2021-12-28 |
2023-07-06 |
Astrazeneca Uk Limited |
Combination of antibody-drug conjugate and rasg12c inhibitor
|
WO2023126823A1
(en)
|
2021-12-28 |
2023-07-06 |
Astrazeneca Uk Limited |
Combination of antibody-drug conjugate and atr inhibitor
|
WO2023152581A1
(en)
|
2022-02-09 |
2023-08-17 |
Janssen Biotech, Inc. |
Method of treating cancer with psmaxcd3 antibody
|
WO2023166081A1
(en)
|
2022-03-02 |
2023-09-07 |
Heidelberg Immunotherapeutics Gmbh |
Vaccine comprising an antibody or an fc-containing fusion protein comprising an fc part of an antibody
|
WO2023175614A1
(en)
|
2022-03-15 |
2023-09-21 |
Yeda Research And Development Co. Ltd. |
Anti glucocorticoid-induced tnfr-related (gitr) protein antibodies and uses thereof
|
WO2023175483A1
(en)
|
2022-03-16 |
2023-09-21 |
Astrazeneca Uk Limited |
A scoring method for an anti-trop2 antibody‑drug conjugate therapy
|
WO2023209591A1
(en)
|
2022-04-27 |
2023-11-02 |
Daiichi Sankyo Company, Limited |
Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor
|
WO2023218378A1
(en)
|
2022-05-11 |
2023-11-16 |
Daiichi Sankyo Company, Limited |
Combination of an antibody specific for a tumor antigen and a cd47 inhibitor
|
WO2023228095A1
(en)
|
2022-05-24 |
2023-11-30 |
Daiichi Sankyo Company, Limited |
Dosage regimen of an anti-cdh6 antibody-drug conjugate
|
WO2024013723A1
(en)
|
2022-07-15 |
2024-01-18 |
Pheon Therapeutics Ltd |
Antibody drug conjugates that bind cdcp1 and uses thereof
|
WO2024023750A1
(en)
|
2022-07-28 |
2024-02-01 |
Astrazeneca Uk Limited |
Combination of antibody-drug conjugate and bispecific checkpoint inhibitor
|
WO2024072893A1
(en)
|
2022-09-28 |
2024-04-04 |
Incyte Corporation |
Anti-pd-1/lag-3 bispecific antibodies and uses thereof
|
WO2024074498A1
(en)
|
2022-10-04 |
2024-04-11 |
Imcheck Therapeutics |
Combination of a btn3a activating antibody, a bcl2 inhibitor and hypomethylating agent for use in treating cancer
|